US20020099003A1 - Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof - Google Patents

Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof Download PDF

Info

Publication number
US20020099003A1
US20020099003A1 US09/929,818 US92981801A US2002099003A1 US 20020099003 A1 US20020099003 A1 US 20020099003A1 US 92981801 A US92981801 A US 92981801A US 2002099003 A1 US2002099003 A1 US 2002099003A1
Authority
US
United States
Prior art keywords
vip
seq
vasoactive
formulation
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/929,818
Inventor
Leland Wilson
Virgil Place
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivus LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/959,064 external-priority patent/US5877216A/en
Application filed by Individual filed Critical Individual
Priority to US09/929,818 priority Critical patent/US20020099003A1/en
Assigned to VIVUS, INC. reassignment VIVUS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLACE, VIRGIL A., WILSON, LELAND F.
Publication of US20020099003A1 publication Critical patent/US20020099003A1/en
Priority to US11/262,067 priority patent/US7226910B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/17—Vasoactive intestinal peptides; related peptides

Definitions

  • This invention relates generally to methods and pharmaceutical formulations for treating female sexual dysfunction, and more particularly relates to vaginal and/or vulvar administration of a vasoactive agent, such as a prostaglandin or a vasoactive intestinal polypeptide, in such treatment.
  • a vasoactive agent such as a prostaglandin or a vasoactive intestinal polypeptide
  • the invention further relates to additional methods of using the present pharmaceutical formulations, including, but not limited to, the prevention of yeast infections and the improvement of vaginal muscle tone.
  • Vasoactive intestinal polypeptide (“VIP”) release may induce the physiological changes of sexual arousal and excitement, and may be the major neurotransmitter effecting neurologically controlled increase of the vaginal blood supply upon arousal.
  • the peptide histidine methionine has been co-located with VIP within nerve fibers that innervate small blood vessels, smooth muscle and epithelial cells in the vaginal tract.
  • VIP is a neurotransmitter known to effect small vessel dilation in the mesenteric blood supply in response to mechanical sensation of food in the gut to promote digestion. VIP is therefore found in the cholinergic, parasympathetic ganglia of the intestinal peripheral nervous system. Kandel, Schwartz and Jessel, Principles of Neural Science, 4 th Ed. (McGraw-Hill 2000). VIP was initially discovered, isolated and purified from porcine intestine, and the twenty-eight (28) amino acid VIP has extensive homology to secretin and glucagon (Carlquist et al. (1982) Horm. Metab. Res. 14:28-29). VIP is known to exhibit a wide range of biological activities in the gastrointestinal tract and circulatory system.
  • VIP has been shown to stimulate pancreatic and biliary secretion, hepatic glycogenolysis, glucagon and insulin secretion and to activate pancreatic bicarbonate release (Kerrins t al. (1972) Proc. Soc. Exp. Biol. Med. 142:1014-1017; Domschke et al. (1977) Gastroenterology 73:78-480).
  • the physiologic effects of VIP extend outside the digestive system.
  • neurons containing VIP have been localized by immunoassay in cells of the endocrine and exocrine systems, intestine and smooth muscle (Polak et al. (1974) Gut 15:720-724), and has been found to be a neuroeffector of the release of hormones including prolactin (Frawley et al. (1981) Neuroendocrinology 33:79-83), thyroxine (Ahren et al. (1980) Nature 287:343-345), and the aforementioned insulin and glucagon (Schebalin, et al. (1977) Am. J. Physiology E. 232:197-200.
  • VIP is present in neurons and neural junctions in the airways of animal species including man (Dey et al. (1980) Fed. Proc. 39:1062; Said et al. (1974) Ann. N.Y. Acad. Sciences 221:103-114). VIP has also been found to stimulate renin release from the kidney in vivo and in vitro (Porter et al. (1983) Neuroendocrinology 36:404-408), and the presence of VIP in other parts of the genito-urinary system has been shown. The widely appreciated direct vasoactive effect of VIP is to increase blood flow into capillary bed by dilation of the afferent blood vessel.
  • Sexual excitement is initiated by any of a number of psychogenic or somatogenic stimuli and must be reinforced to result in orgasm. With continued stimulation, excitement progresses in intensity into a plateau stage, from which the individual can shift into orgasm.
  • the orgasmic stage is characterized by a rapid release from vasocongestion and muscular tension.
  • Excitement stage dysfunction generally involves touch sensation impairment, loss of clitoral sensation, vaginal dryness and urinary incontinence. Such excitement phase dysfunction generally results in dyspareunia. Dyspareunia is thought to affect approximately 40% of women, due in large part to inadequate lubrication. It has been estimated that over 40 million women will suffer dyspareunia at some time in their lives. On the order of twenty-five million women will experience dyspareunia in the peri- and postmenopausal period (see Kelly, S. (1992) Clinical Practice and Sexuality 8(8):2 and Sato et al. (1992) Clinical Practices in Sexuality 8(5):1).
  • Contemporary symptomatic treatments generally involve the use of physiologically safe lubricants such as egg white, K-Y surgical lubrication jelly (hydroxyethyl-cellulose), Astroglide7, and Replens7. See, for example, Semmens (1974) Medical Aspects of Human sexuality 8:85-86, and Frishmen et al. (1992) Fertility and Sterility 8(3):630. When symptomatic treatment fails, pharmacological treatment may be indicated.
  • physiologically safe lubricants such as egg white, K-Y surgical lubrication jelly (hydroxyethyl-cellulose), Astroglide7, and Replens7.
  • Estrogen therapy is commonly used in the pharmacological treatment of sexual dysfunction in women.
  • Estrogen-based therapies are generally used to increase mucous production, provide vasodilatory effects, or to increase the general health of the vagina. Nadelson et al., eds., Treatment Interventions in Human sexuality (New York: Plenum Press, 1983).
  • estrogen is administered orally, parenterally (e.g., by injection), or topically.
  • the estrogen concentration encountered by the liver is generally four- to five-fold greater than estrogen levels in peripheral blood (the “first pass effect”). This effect may lead to an undesirable increase in the production of certain coagulation factors and renin substrates by the liver.
  • Parenterally administered estrogen avoids the first pass effect in the liver.
  • all estrogen-based therapies are known to increase the risk of endometrial hyperplasia, endometrial cancer and breast cancer in treated individuals.
  • estrogen/progestogen combinations have been employed.
  • progestogens are known to have some androgenic activity.
  • common side effects from such therapies include uterine bleeding and the continuation of menstrual periods. Accordingly, there remains a need in the art to provide safer and more ways of treating female sexual dysfunction.
  • the present invention is directed to the aforementioned need in the art, and provides a new, highly effective method of treating sexual dysfunction in women.
  • the method involves vaginal and/or vulvar administration of a pharmaceutical formulation containing a vasoactive agent, e.g., a prostaglandin, VIP or a VIP agonist or the like.
  • a vasoactive agent e.g., a prostaglandin, VIP or a VIP agonist or the like.
  • U.S. Pat. No. 4,521,421 to Foreman describes the treatment of sexual dysfunction in male and female individuals using the stereoisomers of octahydropyrimido[4,5-g]quinolines, centrally acting dopamine agonists.
  • U.S. Pat. Nos. 5,565,466 to Gioco et al., 5,731,339 to Lowrey, and 5,773,457 to Nahoum pertain to methods for modulating the human sexual response, with the Gioco et al. and Lowrey patents emphasizing the utility of phentolarnine as an active agent.
  • references describe various methods and devices suitable for vaginal or uterine drug administration, and may accordingly be of some interest with respect to the present invention.
  • the following are representative of such references:
  • U.S. Pat. No. 3,967,618 to Zaffaroni describes an intrauterine device adapted for drug delivery. A number of drugs are mentioned as being suitable for use in conjunction with the device. However, the patent does not mention treatment of sexual dysfunction, nor is application of a drug-containing composition to the clitoris or vulvar region disclosed or suggested.
  • U.S. Pat. No. 3,948,254 to Zaffaroni is a related patent that describes an intrauterine device for continuous administration of a contraceptive agent.
  • U.S. Pat. No. 4,014,987 to Heller et al. describes a tampon-like device for delivery of a drug to the uterus or vagina.
  • Heller et al. mention that delivery of prostaglandins is a preferred use of the invention; however, there is no disclosure concerning treatment of sexual dysfunction or delivery to the vulvar area or urethra.
  • vasoactive agents such as a prostaglandin or VIP or a receptor agonist thereof.
  • vasoactive agent is vasoactive intestinal polypeptide or an agonist thereof.
  • a method for treating sexual dysfunction in a female individual comprising administering to the vagina and/or vulvar area a pharmaceutical formulation containing a selected vasoactive agent.
  • the vasoactive agent is preferably a vasodilator, with preferred vasodilators selected from the group consisting of VIP and vasoactive intestinal polypeptide agonists, both natural and synthetic, and combinations of any of the foregoing.
  • Any number of drug delivery platforms may be used, e.g., suppositories, ointments, creams, gels, solutions and the like, which will be described in detail below.
  • vaginal administration of a vasoactive agent as just described is used to improve vaginal muscle tone and tissue health, to enhance vaginal lubrication, or to minimize collagen misdeposition resulting from hypoxia as well as the associated lack of elasticity resulting from the collagen misdeposition.
  • compositions and dosage forms are provided for carrying out the aforementioned methods.
  • the compositions and dosage forms contain a vasoactive agent as described above, a pharmaceutically acceptable vehicle, and, optionally, one or more additional pharmacologically active agents.
  • the formulations contain a therapeutically effective amount of the active agent, or a therapeutically effective concentration of the active agent, i.e., a concentration that provides a therapeutically effective amount of active agent upon administration of a selected volume of composition.
  • packaged kits are provided for individuals to carry out the aforementioned methods.
  • Packaged kits include a pharmaceutical composition or dosage form containing the active agent, a container housing the composition or dosage form during storage and prior to administration, and instructions, e.g., written instructions on a package insert or label, for carrying out drug administration in a therapeutically effective manner.
  • the composition or dosage form may be any of those described herein.
  • vasoactive agent includes a mixture of two or more vasoactive agents
  • pharmaceutically acceptable excipient includes mixtures of such excipients, and the like.
  • active agent pharmaceutically active agent
  • drug drug
  • the terms “active agent,” “pharmacologically active agent” and “drug” are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological, physiological effect, i.e., in this case, enhancement of female sexual desire and responsiveness.
  • the primary active agents herein are vasoactive intestinal polypeptide and agonists thereof.
  • the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, and the like.
  • active agent pharmaceutically active agent
  • drug drug
  • the pharmacologically active agents herein are vasoactive intestinal polypeptide and analogs thereof that serve as VIP agonists.
  • “pharmaceutically acceptable,” such as in the recitation of a “pharmaceutically acceptable carrier,” or a “pharmaceutically acceptable acid addition salt,” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • “Pharmacologically active” or simply “active” as in a “pharmacologically active” derivative or metabolite, refers to a derivative or metabolite having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
  • pharmaceutically acceptable refers to a derivative (e.g., a salt) of an active agent, it is to be understood that the compound is pharmacologically active as well, i.e., therapeutically effective to enhance female sexual desire and responsiveness.
  • Carriers or “vehicles” as used herein refer to conventional pharmaceutically acceptable carrier materials suitable for drug administration, and include any such materials known in the art that are nontoxic and do not interact with other components of a pharmaceutical composition or drug delivery system in a deleterious manner.
  • an “effective” amount or a “therapeutically effective amount” of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect, i.e., treatment of female sexual dysfunction.
  • the amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • treating and “treatment” as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.
  • “treating” sexual dysfunction encompasses both prevention of sexual dysfunction in clinically asymptomatic individuals and treatment of dysfunction in a clinically symptomatic individual.
  • treating female sexual dysfunction is meant enhancing female sexual desire and responsiveness.
  • Applicants intend to include the treatment of disorders of female sexual desire and/or response, meaning any disorder or dysfunction that causes a decrease in or absence of female sexual responsiveness or female sexual desire. This includes any persistent or recurrent deficiency in the desire for sexual activity.
  • This term also includes substance-induced sexual dysfunction, including but not limited to, decreases in desire and responsiveness secondary to anti-depressants, neuroleptics, anti-hypertensives, tobacco, opiates, alcohol and any other drug found to decrease or eliminate any part of the sexual response cycle.
  • Primary and secondary anorgasmia are included.
  • “as-needed” dosing also referred to as “pro re nata” dosing, “pm” dosing, and “on-demand” dosing or administration, is meant the administration of an active agent at a time just prior to the time at which drug efficacy is wanted, e.g., just prior to anticipated sexual activity, and within a time interval sufficient to provide for the desired therapeutic effect, i.e., enhancement in sexual desire and in sexual responsiveness during sexual activity.
  • “As-needed” administration herein does not involve priming doses or chronic administration, “chronic” meaning administration at regular time intervals on an ongoing basis.
  • As-needed administration may involve administration immediately prior to sexual activity, but will generally be about 0.25 to 72 hours, preferably about 0.5 to 48 hours, more preferably about 1 to 24 hours, most preferably about 1 to 12 hours, and optimally about 1 to 4 hours prior to anticipated sexual activity. “As-needed” administration may or may not involve administration of a sustained release formulation in advance of anticipated sexual activity, with drug release taking place throughout an extended drug delivery period typically in the range of about 4 to 72 hours.
  • controlled release is intended to refer to any drug-containing formulation in which release of the drug is not immediate, i.e., with a “controlled release” formulation, oral administration does not result in immediate release of the drug into an absorption pool.
  • controlled release is used interchangeably with “nonimmediate release” as defined in Remington: The Science and Practice of Pharmacy, Nineteenth Ed . (Easton, Pa.: Mack Publishing Company, 1995).
  • immediate and nonimmediate release can be defined kinetically by reference to the following equation:
  • the “absorption pool” represents a solution of the drug administered at a particular absorption site, and k r , k a and k e are first-order rate constants for (1) release of the drug from the formulation, (2) absorption, and (3) elimination, respectively.
  • the rate constant for drug release k r is far greater than the absorption rate constant k a .
  • the opposite is true, i.e., k r ⁇ k a , such that the rate of release of drug from the dosage form is the rate-limiting step in the delivery of the drug to the target area.
  • controlled release as used herein includes any nonimmediate release formulation, including but not limited to sustained release, delayed release and pulsatile release formulations.
  • sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
  • a sustained release formulation may be administered once to provide a single bolus dose of the active agent, which is then effective for up to a day or even up to several days.
  • transdermal drug delivery delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream.
  • Topical administration is used in its conventional sense to mean delivery of a topical drug or pharmacologically active agent to the skin or mucosa. Topical administration thus includes transmucosal administration.
  • vaginal delivery of a pharmaceutical formulation involves administration to the distal several centimeters of the vagina.
  • vulvar delivery and “vulvar administration” are used herein to refer to application of a pharmaceutical formulation to the vulvar area of an individual undergoing treatment. The term is intended to encompass application to the clitoris as well as the surrounding vulvar area.
  • vulvar delivery and “clitoral delivery” are used interchangeably herein and are both intended to refer to administration to the vulvar area of the individual undergoing treatment.
  • VIP or an agonist thereof is administered to the vagina and/or vulvar region of a female individual to enhance sexual desire and responsiveness; the individual may or may not be suffering from a sexual disorder or dysfunction.
  • the active agent is administered locally and transmucosally, i.e., vaginally and/or to the vulvar region.
  • C 1-3 alkyl refers to methyl, ethyl, propyl, and isopropyl.
  • vasoactive intestinal peptides of the invention is that typically used in the art, wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right.
  • natural amino acids is meant one of the naturally occurring amino acids found in proteins, i.e., Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp, and His.
  • Nle is meant norleucine.
  • Orn is meant ornithine.
  • Ac is meant acetyl (CH 3 CO 2 ). Where the amino acid has isomeric forms, it is the L form of the amino acid that is represented unless otherwise expressly indicated.
  • Analogs of VIP i.e., those analogs included herein as VIP agonists, are indicated by setting forth the substituted amino acid in brackets before “VIP.” Derivatization of the N-terminal amino group is indicated to the left of the bracketed substitutions. Sequence numbers appearing in parentheses to the right of “VIP” indicate amino acid deletions and additions to the native sequence numbering.
  • Ac-[Lys 12 ,Nle 17 ,Gly 29 ]-VIP(2-29) indicates a polypeptide having an amino acid sequence corresponding to native human VIP in which an acetyl group has been substituted for hydrogen at the N-terminus, lysine has been substituted for arginine at position 12 and norleucine has been substituted for methionine at position 17, the histidine at position 1 has been deleted and a glycine has been coupled onto the carboxyl side of asparagine 28, termed position 29.
  • the suffixes “—OH” and “—NH 2 ” following “VIP” refer to the free acid and amide forms of the polypeptide, respectively. In the event neither suffix is used, the expression is intended to encompass both forms.
  • N—CH 3 -Ala is N-methyl-alanine
  • p-F-Phe is fluoro-phenylalanine
  • 1-Nal is 3-(1′-naphthyl)-alanine
  • 2-Nal is 3-(2′-naphthyl)-alanine
  • p-NH 2 -Phe is p-amino-phenylalanine
  • O—CH 3 -Tyr is O-methyl-tyrosine
  • Cys(Acm) is S-acetoamidomethyl-cysteine
  • m-F-Tyr is m-fluoro-tyrosine.
  • the invention in a first embodiment, relates to a method for treating sexual dysfunction in a female individual and involves vaginal and/or vulvar administration of a pharmaceutical formulation containing a vasoactive agent, preferably a vasodilator.
  • a vasoactive agent preferably a vasodilator.
  • Preferred vasodilators are selected from the group consisting of vasoactive intestinal polypeptide, VIP agonists, pharmaceutically acceptable salts, esters, derivatives, prodrugs, and inclusion complexes thereof, and combinations of any of the foregoing, in combination with a pharmaceutically acceptable vehicle.
  • VIP agonists are, as noted above, useful for practicing the invention.
  • the sequence of human VIP, which is the same as rat, bovine and porcine VIP is known to be:
  • the VIP amino acid sequence is: H-S-D-A-V-F-T-D-N-Y-T-R-L-R-K-Q-M-A-V-K-K-Y-L-N-S-I-L-N (SEQ. ID. NO.: 1).
  • VIP sequences from other species are known to exhibit homology to human VIP and therefore expected to exhibit VIP agonistic and/or antagonistic activity.
  • Partial agonists of VIP that are also antagonists of VIP for example agonists that are less active than endogenously secreted VIP may be used in the methods of the invention depending upon activity relative to physiologic human VIP and local dosage.
  • the usefulness of partial VIP agonists for practicing the invention may be ascertained by conventional trials and pharmacologic assays known in the art.
  • vasoactive intestinal polypeptide analogs include peptides having the following amino acid sequences:
  • vasoactive intestinal polypeptide analogs include the following:
  • VIP analogs known in the art include:
  • the preceding list of VIP agonists is by way of example rather than limitation, and other known VIP agonists include permutations of the preceding amino acid sequences and lesser-included deviations from the VIP sequence. Permutations include, for example sequences such as [Thr 18 ]-VIP (SEQ. ID. NO.: 201), which is not listed explicitly above but is a lesser-included deviation from the naturally occurring human VIP sequence that is described, for example, in Ac-[Lys 12 ,Nle 17 ,Val 26 ,Ala 27 ,Thr 28 ]-VIP (SEQ. ID. NO.: 21) and Ac-[Lys 12 ,Nle 17 ,Ala 16 ,Thr 28 ]-VIP (SEQ. ID.
  • SEQ. ID. NO.: 22 As well as a number of other of the above listed VIP analog sequences, for example, SEQ. ID. NO.: 46.
  • SEQ. ID. NO. 21 and SEQ. ID. NO. 22 Further a permutation of SEQ. ID. NO. 21 and SEQ. ID. NO. 22, is exemplified by Ac-[Lys 12 ,Nle 17 ,Ala 26 ,Ala 27 ,Thr 28 ]-VIP (SEQ. ID. NO.: 202), which substitutes the Ala 26 of SEQ. ID. NO.:22 for the Val 26 of SEQ. ID. NO.: 21 and is otherwise identical to SEQ. ID. NO.:21.
  • Analogs for use with the instant invention are intended that are essentially equivalent to an explicitly disclosed analog, as specified above.
  • An analog is essentially equivalent to one specified above if it has one or more of the biological activities characteristic of human VIP, has the same number of amino acids as the specified analog and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like).
  • acidic amino acids are Asp, Glu and gamma-carboxyglutamic acid
  • basic amino acids are Arg, Lys, His and Orn
  • hydrophobic amino acids are Ala, Ile, Leu, Met, Nor, Phe, Trp, Tyr, Val, t-butylglycine, norvaline, cyclohexylalanine, t-butylalanine, amino-4-phenylbutyric acid, beta-2-thienylalanine, p-bromophenylalanine, p-chlorophenylalanine, p-iodophenylalanine, p-nitrophenylalanine, 3,5-diiodotyrosine, phenylglycine, and naphthylalanine; uncharged polar amino acids are Asn, Gln, Ser, and Thr.
  • Gly can be substituted for an uncharged polar or a hydrophobic amino acid, but substitutions with Gly are often avoided because helical structures may be destabilized thereby. Substitutions with Pro are generally avoided because of a significant effect on secondary structure of inserting a Pro in place of another amino acid. Substitutions with Cys are also generally avoided because of the reactivity of the sulfhydryl group.
  • VIP agonists include conjugates of VIP and long chain fatty acids or fatty amines, such as CH 3 (CH 2 ) 6 CO-VIP, CH 3 (CH 2 ) 16 CO-VIP, CH 3 (CH 2 ) 16 CO-VIP 7-28 , CH 3 (CH 2 ) 16 CO-VIP 16-28 , VIP-CONH—CH 2 CH 3 , VIP-CONH—(CH 2 ) 3 CH 3 , and VIP-CONH-(CH 2 ) 7 CH 3 , the synthesis of which is described in U.S. Pat. No. 5,147,855 to Gozes et al.
  • VIP agonists are nitrosylated VIP analogs having the structure VIP-Gly-Cys-NO (SEQ. ID NO.: 203), and the related analogs VIP-Gly-Cys-NH 2 (SEQ. ID NO.: 204) and VIP-Gly-Cys (SEQ. ID NO.: 205), preparation of which is described in U.S. Pat. No. 5,612,314 to Stamler et al.
  • VIP analogs known in the art that are useful for practicing the present invention include those compounds listed above and others that exhibit agonistic VIP activity, preferably strong agonistic activity. Also preferred are those analogs that exhibit agonistic activity with a relatively long biological activity, e.g. a relatively long pharmacologic half-life. Methods for determining the agonistic VIP activity and half-life of a given VIP analog are known to those ordinarily skilled in the art.
  • One attribute of a VIP analog that makes it useful for practicing the invention is a resistance to hydrolysis, a property of synthetic VIP analogs that are disclosed in U.S. Pat. No. 4,939,224 to Musso et al. for bronchodilation.
  • the above representative VIP analogs may be readily synthesized by known conventional techniques for forming a peptide linkage between amino acids.
  • Such conventional procedures include, for example, all solution phase techniques permitting a condensation between the free alpha amino group of an amino acid or residue thereof having its carboxyl group or other reactive groups protected and the free primary carboxyl group of another amino acid or residue thereof having its amino group or other reactive groups protected.
  • the process for synthesizing the representative compounds may be carried out by a procedure whereby each amino acid in the desired sequence is added one at a time in succession to another amino acid or residue thereof or by a procedure whereby peptide fragments with the desired amino acid sequence are first synthesized conventionally and then condensed to provide the desired peptide.
  • Such conventional procedures for synthesizing the active agents of the present invention include for example any solid phase peptide synthesis method.
  • the synthesis of the active agents can be carried out by sequentially incorporating the desired amino acid residues one at a time into the growing peptide chain according to the general principles of solid phase methods (Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2154; Barany et al, The Peptides, Analysis, Synthesis and Biology, Vol. 2, 1-284 Gross, E. and Meienhofer, J., Eds. (Academic Press 1980)).
  • Additional pharmacologically active agents may be co-administered along with the primary active agent, i.e., with the VIP or VIP agonist.
  • additional active agents are also referred to herein as “secondary” active agents.
  • Preferred secondary agents are vasoactive agents, particularly vasodilators, selected from the group consisting of vasoactive prostaglandins, endothelin-derived relaxation factors, smooth muscle relaxants, leukotriene inhibitors, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs, active metabolites, and inclusion complexes thereof, and combinations of any of the foregoing.
  • Suitable secondary agents include rho kinase inhibitors, melanocortin peptides, endothelin antagonists, growth factors and other peptidyl drugs; selective androgen receptor modulators (SARMs), neuropeptides, amino acids, serotonin agonists, serotonin antagonists, calcium channel blockers, potassium channel openers, potassium channel blockers, dopamine agonists, dopamine antagonists, non-androgenic steroid hormones, and combinations thereof.
  • SARMs selective androgen receptor modulators
  • vasoactive agents are vasoactive prostaglandins selected from the group consisting of naturally occurring prostaglandins, semisynthetic prostaglandins, synthetic prostaglandins, and pharmaceutically acceptable, pharmacologically active salts, esters, amides, inclusion complexes prodrugs, metabolites, and analogs thereof. Racemic, optically enriched or purified stereoisomers of any of these compounds are also included.
  • a suitable unit dose of a prostaglandin herein is in the range of approximately 1 to 5000 ⁇ g, preferably in the range of approximately 20 to 2000 ⁇ g.
  • Preferred prostaglandins include, but are not limited to, the naturally occurring prostaglandins prostaglandin E 0 (PGE 0 , also referred to 13,14-dihydro-PGE 1 , hereinafter, the abbreviation “PG” is used for “prostaglandin”), PGE 1 , 19-hydroxy-PGE 1 , PGE 2 , 19-hydroxy-PGE 2 ,PGA 1 , 19-hydroxy-PGA 1 , PGA 2 , 19-hydroxy-PGA 2 , PGB 1 , 19-hydroxy-PGB 1 , PGB 2 , 19-hydroxy-PGB 2 , PGB 3 , PGD 2 , PGF 1 ⁇ , PGF 2 ⁇ ,(dinoprost), PGE 3 , PGF 3 ⁇ , PGI 2 (prostacyclin), and combinations thereof.
  • PGE 0 , PGE 1 , PGE 2 , and the hydrolyzable lower alkyl esters thereof are, however, particularly preferred.
  • Other suitable prostaglandins are exemplified, without limitation, by arboprostil, carbaprostacyclin, carboprost tromethamine, dinoprost tromethamine, dinoprostone, enprostil, iloprost, lipoprost, gemeprost, metenoprost, sulprostone, tiaprost, viprostil (CL 115,347), viprostil methyl ester, 16,16-dimethyl- ⁇ 2 -PGE 1 , methyl ester, 15-deoxy-16-hydroxy-16-methyl-PGE 1 , methyl ester (misoprostol), 16,16-dimethyl-PGE 1 , 11-deoxy-15-methyl-PGE 1
  • Additional vasoactive agents useful as secondary active agents herein include endothelin-derived relaxation factors (“EDRFs”) such as nitric oxide releasing agents, e.g., sodium nitroprusside and diazenium diolates, or “NONOates.”
  • NONOates include, but are not limited to, (Z)-1- ⁇ N-methyl-N-[6-(N-methyl-ammoniohexyl)amino] ⁇ diazen-1-ium-1,2-diolate (“MAHMA/NO”), (Z)-1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]-diazen-1-ium-1,2-diolate (“PAPA/NO”), (Z)-1- ⁇ N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]amino ⁇ diazen-1-ium-1,2-diolate (spermine NO
  • vasoactive agents include vasoactive intestinal polypeptide analogs and derivatives thereof (particularly derivatives in the form of hydrolyzable lower alkyl esters), smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, ⁇ 2-adrenergic agonists, angiotensin-converting enzyme (“ACE”) inhibitors, angiotensin II receptor antagonists, and phosphodiesterase inhibitors.
  • ACE angiotensin-converting enzyme
  • vasoactive agents include, but are not limited to: nitrates and like compounds such as nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, molsidomine, linsidomine chlorhydrate (“SIN-1”), S-nitroso-N-acetyl-d,1-penicillamine (“SNAP”) and S-nitroso-N-glutathione (“SNO-GLU”); long and short acting ⁇ -blockers such as phenoxybenzamine, dibenamine, doxazosin, terazosin, phentolamine, tolazoline, prazosin, trimazosin, alfuzosin, tamsulosin and indoramin; ergot alkaloids such as ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianer
  • Other secondary active agents herein are inhibitors of rho kinase, an enzyme belonging to the rhoA/rho associated kinase pathway, which regulates the state of phosphorylation of myosin phosphatase, in turn leading to the control of smooth muscle contraction.
  • rho kinase an enzyme belonging to the rhoA/rho associated kinase pathway, which regulates the state of phosphorylation of myosin phosphatase, in turn leading to the control of smooth muscle contraction.
  • rho kinase inhibitor has the structural formula
  • Additional secondary agents useful herein are peptide analogs of ⁇ -melanocyte-stimulating hormone ( ⁇ -MSH), also referred to as “melanocortin peptides.”
  • ⁇ -MSH ⁇ -melanocyte-stimulating hormone
  • Such peptides include the sequence His-Phe-Arg-Trp, His-D-Phe-Arg-Trp, or are homologs thereof, and are preferably cyclic.
  • a preferred melanocortin peptide is Ac-Nle-cyclo-(-Asp-His-D-Phe-Arg-Trp-Lys)—OH. See U.S. Pat. No. 6,051,555 to Hadley and International Patent Publication No. WO 01/00224 to Blood et al., assigned to Palatin Technologies, Inc.
  • Arg is arginine
  • Nle is norleucine
  • His is histamine
  • Phe is phenylalanine
  • D-Phe is D-phenylalanine
  • Trp is tryptophan
  • Ac refers to an acetyl moiety, i.e., an acetyl moiety present in a peptide or amino acid sequence that is acetylated.
  • Suitable endothelin antagonists include antagonists of any or all of the three isoforms of endothelin, i.e., ET-1, ET-2, and ET-3, and are exemplified by: phenoxyphenylacetic acids and derivatives thereof, such as N-(4-isopropylbenzene-sulbonyl)- ⁇ -(4-carboxy-2-n-propylphenoxy)-3,4-methylenedioxyphenyl acetamide dipotassium salt, 2-[(2,6-dipropyl-4-hydroxymethyl)-phenoxy]-2-(4-phenoxyphenyl)-acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(4-phenylphenyl)acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3-carboxyphenyl)-acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phen
  • Peptidyl drugs include the peptidyl hormones activin, amylin, angiotensin, atrial natriuretic peptide (ANP), calcitonin, calcitonin gene-related peptide, calcitonin N-terminal flanking peptide, ciliary neurotrophic factor (CNTF), corticotropin (adrenocorticotropin hormone, ACTH), corticotropin-releasing factor (CRF or CRH), epidermal growth factor (EGF), follicle-stimulating hormone (FSH), gastrin, gastrin inhibitory peptide (GIP), gastrin-releasing peptide, gonadotropin-releasing factor (GnRF or GNRH), growth hormone releasing factor (GRF, GRH), human chorionic gonadotropin (hCH), inhibin A, inhibin B, insulin, luteinizing hormone (LH), luteinizing hormone-releasing hormone (LHRH), ⁇ -melanocyte-
  • peptidyl drugs are the cytokines, e.g., colony stimulating factor 4, heparin binding neurotrophic factor (HBNF), interferon- ⁇ , interferon ⁇ -2a, interferon ⁇ -2b, interferon ⁇ -n3, interferon- ⁇ , etc., interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, etc., tumor necrosis factor, tumor necrosis factor- ⁇ , granuloycte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor, midkine (MD), and thymopoietin.
  • cytokines e.g., colony stimulating factor 4, heparin binding neurotrophic factor (HBNF), interferon- ⁇ , interferon ⁇ -2a, interferon ⁇ -2b,
  • SARMs include LGD2226 and/or LGD1331, both available from Ligand Pharmaceuticals (San Diego, Calif.). See Negro-Villar et al. (1999) J. Clin. Endocrinol. & Metabol. 84(10):3459-62.
  • Suitable neuropeptides include bradykinin, kallidin, des- Arg 9 -bradykinin, des-Arg 10 -kallidin, des-Arg 9 -[Leu 8 ]-bradykinin, [D-Phe 7 ]-bradykinin, HOE 140, neuropeptide Y, calcitonin gene-related peptide (cGRP), enkaphalins and related opioid peptides such as Met 5 -enkaphalin, Leu 5 -enkephalin, ⁇ -, ⁇ - and ⁇ -endorphin, ⁇ - and ⁇ - neo-endorphin, and dynorphin, as well as the neurotransmitters GABA ( ⁇ -aminobutyric acid), glycine, glutamate, acetylcholine, dopamine, epinephrine, 5-hydroxytryptamine, substance P, serotonin, and catecholamines.
  • GABA ⁇ -amin
  • amino acid includes the conventional amino acids, e.g., phenylalanine, leucine, isoleucine, methionine, valine, serine, proline, threonine, alanine, tyrosine, histidine, glutamine, asparagine, lysine, aspartic acid, glutamic acid, cysteine, tryptophan, arginine, and glycine, with arginine being particularly preferred.
  • amino acid will also include amino acid derivatives, e.g., 1-naphthylalanine, 2-naphthylalanine, 3-pyridylalanine, 4-hydroxyproline, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and nor-leucine, in addition to stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids. Combinations of any of the foregoing are contemplated as well.
  • Preferred amino acids are the neuroactive amino acids ⁇ -aminobutyric acid (GABA), glycine, ⁇ -alanine, taurine, and glutamate.
  • Suitable serotonin agonists include, but are not limited to 2-methyl serotonin, buspirone, ipsaperone, tiaspirone, gepirone, ergot alkaloids, 8-hydroxy-(2-N,N-dipropyl-amino)-tetraline, 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane, cisapride, sumatriptan, m-chlorophenylpiperazine, trazodone, zacopride, mezacopride, and combinations thereof.
  • Suitable serotonin antagonists include, for example, ondansetron, granisetron, metoclopramide, tropisetron, dolasetron, palonosetron, trimethobenzamide, methysergide, risperidone, ketanserin, ritanserin, clozapine, amitriptyline, MDL 100,907 (R(+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine-methanol) (Marion Merrell Dow), azatadine, cyproheptadine, fenclonine, chlorpromazine, mianserin and combinations thereof.
  • Representative ergot alkaloids include ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile, dihydroergotamine, disulergine, ergonovine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride and terguride.
  • ergotamine and ergotamine analogs e.g., acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile, dihydroergotamine, disulergine, ergonovine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesuler
  • Calcium channel blockers that are suitable for use according to the present invention include, without limitation, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, bepridil, diltiazem, verapamil, and combinations thereof.
  • Potassium channel openers include, but are not limited to, pinacidil, diazoxide, cromakalim, nicorandil, minoxidil, (N-cyano-N′-(1,1-dimethylpropyl)-N′′-3-pyridyl-guanidine (P-1075), and N-cyano-N′-(2-nitroxyethyl)-3-pridinecarboximidamide monomethanesulfonate (KRN 2391).
  • Potassium channel blockers include tedisamil, agitoxin-2, apamin, BDS-I, BDS-II, charybdotoxin, ⁇ -dendrotoxin, ⁇ -dendrotoxin, ⁇ -dendrotoxin, ⁇ -dendrotoxin, dendrotoxin-I, dendrotoxin-K, E-4031, iberiotoxin, kaliotoxin, MCD-peptide, margatoxin, noxiustoxin, paxilline, penitrem A, stichodactyla, tertiapin, tityustoxin K alpha, verruculogen, and combinations thereof. Although all of the active agents are available commercially, most of the listed potassium channel blockers are available from Alomone Labs (Jerusalem, Israel).
  • Suitable dopamine agonists include, for example, levodopa, bromocriptine, pergolide, apomorphine, piribedil, pramipexole, ropinirole, and combinations thereof.
  • Dopamine antagonists include, without limitation, spiroperidol, benperidol, trifluperidol, pimozide, fluphenazine, droperidol, haloperidol, thiothixene, trifluperazine, moperone, prochlorperazine, molindone, thioridazine, clozapine, chlorpromazine, promazine, sulpiride, clebopride, chlorpromazine, spiperone, flupenthixol, and combinations thereof.
  • Non-androgenic steroids that may be administered as secondary active agents include progestins and estrogens.
  • Suitable estrogens include synthetic and natural estrogens such as: estradiol (i.e., 1,3,5-estratriene-3,17 ⁇ -diol, or “17 ⁇ -estradiol”) and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17 ⁇ -estradiol; ethinylestradiol (i.e., 17 ⁇ -ethinylestradiol) and esters and ethers thereof, including ethinylestradiol 3-acetate and ethinylestradiol 3-benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate, and piperazine estrone sulfate;
  • Suitable progestins include acetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17 ⁇ -ethinyltestosterone), ethynodiol diacetate, flurogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol acetate, norethindrone, norethindrone acetate, norethisterone
  • estrogen-based therapies are known to increase the risk of endometrial hyperplasia and cancer, as well as the risk of breast cancer, in treated individuals.
  • Co-administration of estrogenic agents with a progestin has been found to decrease the aforementioned risks.
  • the primary vasoactive agent i.e., VIP or an agonist thereof
  • the additional active agent or agents may be incorporated into a single formulation, or they may be administered separately, either simultaneously or sequentially.
  • an androgenic agent is administered prior to administration of VIP or a VIP agonist, i.e., the androgenic agent is administered as a pretreatment.
  • such a method involves administration of an androgenic agent, e.g., via oral or topical (preferably vulvar and/or vaginal) administration, followed by topical (again, preferably vulvar and/or vaginal) administration of VIP or a VIP agonist.
  • the formulations herein are administered by topical application to the vulvar region and/or by vaginal drug administration.
  • These pharmaceutical formulations will typically contain one or more pharmaceutically acceptable carriers suited to the particular type of formulation, i.e., gel, ointment, suppository, or the like.
  • the vehicles are comprised of materials of naturally occurring or synthetic origin that do not adversely affect the active agent or other components of the formulation.
  • Suitable carriers for use herein include water, silicone, waxes, petroleum jelly, polyethylene glycol, propylene glycol, liposomes, sugars such as mannitol and lactose, and a variety of other materials, again depending, on the specific type of formulation used.
  • dosage forms used for administration to the vulvar region and/or vagina may be used to deliver drug on an as-needed, on-demand basis, and/or throughout an extended, sustained release profile.
  • the formulations may also include a chemical compound to enhance permeation of the active agent through the mucosal tissue, i.e., a “permeation enhancer.”
  • a permeation enhancer include those generally useful in conjunction with topical, transdermal or transmucosal drug delivery.
  • Suitable permeation enhancers include the following: sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C 10 MSO); ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No.
  • sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C 10 MSO)
  • ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether
  • surfactants such as sodium laurate, sodium lauryl sulfate,
  • alcohols such as ethanol, propanol, octanol, decanol, benzyl alcohol, and the like
  • fatty acids such as lauric acid, oleic acid and valeric acid
  • fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate
  • polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No.
  • amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes; alkanones; and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid. Mixtures of two or more enhancers may also be used.
  • the formulations may include an enzyme inhibitor, i.e., a compound effective to inhibit enzymes present in the vagina or vulvar area that could degrade or metabolize the active agent. That is, inhibitors of enzymes that decrease or eliminate the activity of the active agent may be included in the formulation so as to effectively inhibit the action of those enzymes.
  • an enzyme inhibitor i.e., a compound effective to inhibit enzymes present in the vagina or vulvar area that could degrade or metabolize the active agent. That is, inhibitors of enzymes that decrease or eliminate the activity of the active agent may be included in the formulation so as to effectively inhibit the action of those enzymes.
  • Such compounds include, for example, fatty acids, fatty acid esters, and NAD inhibitors.
  • the formulations may be in the form of an ointment, cream, emulsion, lotion, gel, solid, solution, suspension, foam or liposomal formulation.
  • the formulations may be contained within a vaginal ring (e.g., as disclosed in U.S. Pat. No. 5,188,835 to Lindskog et al., assigned to Kabi Pharmacia AB), or within a tampon, suppository, sponge, pillow, puff, or osmotic pump system; these platforms are useful solely for vaginal delivery.
  • Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives.
  • the specific ointment base to be used is one that will provide for optimum drug delivery.
  • an ointment base should be inert, stable, nonirritating and nonsensitizing.
  • ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases.
  • Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum.
  • Emulsifiable ointment bases also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum.
  • Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid.
  • Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy for further information.
  • Lotions are preparations that may be applied without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base.
  • Lotions are usually suspensions of solids, and preferably, for the present purpose, comprise a liquid oily emulsion of the oil-in-water type. It is generally necessary that the insoluble matter in a lotion be finely divided.
  • Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethylcellulose, or the like.
  • compositions are generally formed from a dispersed phase (e.g., a pharmacologically active agent), a dispersion medium and an emulsifying agent. If desired, emulsion stabilizers can be included in the formulation as well.
  • a dispersed phase e.g., a pharmacologically active agent
  • emulsion stabilizers can be included in the formulation as well.
  • a number of pharmaceutically useful emulsions are known in the art, including oil-in-water (o/w) formulations, water-in-oil (w/o) formulations and multiple emulsions such as w/o/w or o/w/o formulations.
  • Emulsifying agents suitable for use in such formulations include, but are not limited to, TWEEN 60®, Span 80®, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
  • Creams are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
  • Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase.
  • the oil phase also sometimes called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
  • the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant.
  • the above pharmaceutical formulations are formed by dispersing the finely divided or dissolved active agent uniformly throughout the vehicle or base using conventional techniques, typically by a levigating the agent with a small quantity of the base to form a concentrate, which is then diluted geometrically with further base.
  • a mechanical mixer may be used.
  • Creams, lotions and emulsions are formed by way of a two-phase heat system, wherein oil-phase ingredients are combined under heat to provide a liquified, uniform system.
  • the aqueous-phase ingredients are separately combined using heat.
  • the oil and aqueous phases are then added together with constant agitation and allowed to cool.
  • concentrated agents may be added as a slurry. Volatile or aromatic materials can be added after the emulsion has sufficiently cooled. Preparation of such pharmaceutical formulations is within the general skill of the art.
  • the active agent can also be incorporated into a gel formulation using known techniques.
  • Two-phase gel systems generally comprise a suspension or network of small, discrete particles interpenetrated by a liquid to provide a dispersed phase and a liquid phase.
  • Single-phase gel systems are formed by distributing organic macromolecules uniformly throughout a liquid such that there are no apparent boundaries between the dispersed and liquid phases.
  • Suitable gelling agents for use herein include synthetic macromolecules (e.g., Carbomers®, polyvinyl alcohols and polyoxyethylene-polyoxypropylene copolymers), gums such as tragacanth, as well as sodium alginate, gelatin, methylcellulose, sodium carboxymethylcellulose, methylhydroxyethyl cellulose and hydroxyethyl cellulose.
  • dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.
  • Liposomes are microscopic vesicles having a lipid wall comprising a lipid bilayer, and can be used as drug delivery systems herein as well. Generally, liposome formulations are preferred for poorly soluble or insoluble pharmaceutical agents. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (“DOTMA”) liposomes are available under the tradename Lipofectin® (GIBCO BRL, Grand Island, N.Y.).
  • DOTMA N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium
  • anionic and neutral liposomes are readily available as well, e.g., from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials.
  • Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (“DOPC”), dioleoylphosphatidyl glycerol (“DOPG”), dioleoylphoshatidyl ethanolamine (“DOPE”), among others. These materials can also be mixed with DOTMA in appropriate ratios. Methods for making liposomes using these materials are well known in the art.
  • Vaginal suppositories are typically manufactured with polyethylene glycol (PEG), polyethylene oxide and/or other low melting point or water-soluble polymers including fatty acid esters. Suppositories may also be applied to the vulvar region, in which case these dosage forms, which are solid at ambient temperature, rapidly melts when placed on the clitoris and within the vulvar region.
  • PEG polyethylene glycol
  • PEG polyethylene oxide
  • water-soluble polymers including fatty acid esters
  • compositions and dosage forms for vulvar and/or vaginal administration will contain the active agent in a concentration such that an effective amount of the agent is delivered with a single application.
  • the composition or dosage form will generally contain sufficient active agent such that an effective amount of the agent is delivered by application of about 0.1 g to 1.0 g.
  • the composition or dosage form will contain the active agent at a concentration in the range of about 1.0 ⁇ g/g to about 1.0 g/g, preferably 50 ⁇ g/g to about 500 mg/g, most preferably about 1.0 mg/g to about 250 mg/g.
  • Delivery of an “as-needed” or “on-demand” dose with topical formulations intended for application to the vulvar region, and/or with vaginal suppositories is effected by using the appropriate carrier and, when necessary, excipients, for the particular active agent.
  • the active agent's affinity to the carrier must be lower than its affinity to the treated body surface.
  • the agent will have a relatively high affinity for the mucosal surface to which it is applied, and a relatively low affinity for the particular carrier.
  • a suitable carrier for use in the formulations described herein can be determined by routinely testing a series of different carriers containing the active agent and selecting those carriers that provide the greatest flux of the active agent to the intended tissue, e.g., clitoral tissue.
  • one or more permeation enhancers and/or detergents may also be present in the formulation to ensure a rate of delivery sufficient for on-demand administration. A combination of these approaches as well as other approaches may be used to effect delivery of an on-demand dose.
  • the drug delivery system if present, and/or any remaining formulation may be removed or may remain in place, depending on the preferences of the individual.
  • the formulation and optional drug delivery system may be designed to provide both initial “on-demand” release of the active agent, i.e., as a single, bolus dose, as well as sustained release thereafter, e.g., pulsatile, continuous or cyclical drug release.
  • Such systems can include, for example, osmotic release systems that are capable of delivering an initial, on-demand release of the active agent in addition to variable amounts of the agent in a pulsatile manner thereafter.
  • Other drug delivery platforms capable of providing an initial release of drug followed by a pulsatile, continuous or cyclical agent release profile include those formed from bioerodible polymers, wherein the active agent is dispersed within a polymer matrix that is surrounded by an immediate release coating of the agent.
  • the immediate release coating ensures effective on-demand administration.
  • the polymers forming the matrix are selected such that they bioerode in the presence of moisture, and provide for sustained agent release at readily predictable rates.
  • release of the active agent can be controlled by dissolution (bioerosion) of a polymer using either encapsulated dissolution control or matrix dissolution control.
  • encapsulated dissolution control the on-demand dose of the active agent is located within an outer polymeric or wax membrane that dissolves to provide an initial release of the agent.
  • a core containing additional active agent is then available for release and adsorption across the epithelial or mucosal surfaces of the vagina or vulvar area.
  • Bioerodible coating materials may be selected from a variety of natural and synthetic polymers, depending on the agent to be coated and the desired release characteristics.
  • Exemplary coating materials include gelatins, carnauba wax, shellacs, ethylcellulose, cellulose acetate phthalate or cellulose acetate butyrate.
  • a uniform sustained release of the agent can be attained by compressing a population of particles of the agent with varying membrane thickness (e.g., varying erosion times) into a tablet form for a single administration.
  • the active agent is dissolved or dispersed within a matrix of, for example, an erodible wax.
  • the agent is released for adsorption across the epithelial or mucosal surfaces of the vagina or vulvar area as the matrix bioerodes.
  • the rate of agent availability is generally controlled by the rate of penetration of the dissolution media (i.e., vaginal fluids) into the matrix, wherein the rate of penetration is dependent on the porosity of the matrix material.
  • Bioerodible matrix dissolution delivery systems can be prepared by compressing the active agent with a slowly soluble polymer carrier into a tablet or suppository form. There are several methods of preparing drug/wax particles including congealing and aqueous dispersion techniques.
  • the active agent is combined with a wax material and either spray-congealed, or congealed and then screened.
  • a wax material for an aqueous dispersion, the active agent/wax combination is sprayed or placed in water and the resulting particles collected.
  • Matrix dosage formulations can be formed by compaction or compression of a mixture of active agent, polymer and excipients.
  • the active agent will also be located in an external coating of the matrix formulation to provide for immediate release of the active agent necessary for on-demand administration.
  • the pharmaceutical formulation is administered in the form of biodegradable adhesive film or sheet that adheres to the vulvar area.
  • biodegradable adhesive film or sheet that adheres to the vulvar area.
  • Such drug delivery systems are generally composed of a biodegradable adhesive polymer based on a polyurethane, a poly(lactic acid), a poly(glycolic acid), a poly(ortho ester), a polyanhydride, a polyphosphazene, or a mixture or copolymer thereof.
  • Preferred biodegradable adhesive polymers include polyurethanes and block copolyurethanes containing peptide linkages, simple mixtures of polyurethanes and polylactides, and copolymers of acrylates and mono- or disaccharide residues.
  • Preferred dosage forms contain a unit dose of active agent, i.e., a single therapeutically effective dose.
  • a “unit dose” requires an active agent concentration that provides a unit dose in a specified quantity of the formulation to be applied, as explained supra.
  • the unit dose of any particular active agent will depend, of course, on the active agent, the needs of the patient, and on the mode of administration.
  • Drug administration is preferably, although not necessarily, on an as-needed basis, in which case chronic drug administration is not involved.
  • an immediate release dosage form i.e., a composition or dosage form that is not “controlled release” as defined hereinabove
  • as-needed administration may involve drug administration immediately prior to sexual activity, but will generally be in the range of about 0.25 to 72 hours, preferably about 0.5 to 48 hours, more preferably about 1 to 24 hours, most preferably about 1 to 12 hours, and optimally about 1 to 4 hours prior to anticipated sexual activity.
  • the upper end of the aforementioned ranges will depend on the pharmacokinetics of the particular active agent administered.
  • a single “as-needed” dose can provide therapeutic efficacy over an extended time period in the range of about 4 to 72 hours, typically in the range of about 4 to 48 hours, more typically in the range of about 4 to 24 hours, depending on the formulation.
  • the release period may be varied by the selection and relative quantity of particular sustained release polymers, as discussed supra.
  • As-needed administration as described herein has several advantages over chronic pharmacologic intervention.
  • chronic administration of some agents, in particular steroids can result in serious medical complications and alter the balance of naturally occurring steroids in the body.
  • patient compliance can be problematic with a regimented dosing scheme.
  • as-needed administration is convenient and doses are taken only in anticipation of sexual activity. Thus, needless expenditure on wasted dosages is avoided, thereby decreasing the treatment's overall expense.
  • the patient treated may be a woman suffering from some type of sexual dysfunction or disorder, or may possess “normal” sexual desire and/or “normal” sexual responsiveness as those terms are understood defined by clinicians or other experts.
  • the present invention offers heightened sexual desire and responsiveness relative to her typical sexual experience.
  • the female patient seeking enhanced sexual desire and responsiveness suffers a sexual dysfunction such as a condition, disease or disorder that affects one of the four stages of the female sexual response: excitement, plateau, orgasm, or resolution. More specifically, the patient may suffer from any one or more of the following:
  • a decrease in the physiological response to sexual stimulation such as, but not limited to, slowed, decreased or absent erectile response of the female erectile tissues; slowed, decrease or absent lubrication of the vagina; slowed decreased or absent ability to reach orgasm, and decreased intensity of or pleasure in orgasms;
  • a condition, disease or disorder that may result in decreased sexual desire and responsiveness including, but not limited to, the menopausal or post-menopausal state, radiotherapy of the pelvis, multiple sclerosis, atherosclerosis, pelvic trauma or surgery, peripheral neuropathies, autonomic neuropathies, diabetes mellitus, and disorders of the innervation of any of the sexual organs;
  • substance-induced decreases in sexual desire and responsiveness including, but not limited to, decreases related to the administration of pharmacologic agents such as, but not limited to, anti-depressants, neuroleptics, anti-hypertensives, opiates, alcohol, and any other agent found to decrease or eliminate any part of the sexual response cycle; and
  • compositions and dosage forms of the invention are useful in improving the tissue health of the female genitalia and preventing vaginal atrophy, preventing pain during intercourse as a result of dyspareunia, and alleviating vaginal itching and dryness associated with dyspareunia and other conditions.
  • a packaged kit contains the pharmaceutical formulation to be administered, i.e., a pharmaceutical formulation containing VIP or a VIP agonist for enhancing female sexual desire and responsiveness, a container (e.g., a vial, a bottle, a pouch, an envelope, a can, a tube, an atomizer, an aerosol can, etc.), preferably sealed, for housing the formulation during storage and prior to use, and instructions for carrying out drug administration in a manner effective to enhance sexual desire and responsiveness.
  • the instructions will typically be written instructions on a package insert, a label, and/or on other components of the kit.
  • the kit may also include a device for administering the formulation (e.g., a transdermal delivery device).
  • the administration device may be a dropper, a swab, a stick, or the nozzle or outlet of an atomizer or aerosol can.
  • the formulation may be any suitable formulation as described herein.
  • the formulation may be an oral dosage form containing a unit dosage of the active agent, or a gel or ointment contained within a tube.
  • the kit may contain multiple formulations of different dosages of the same agent.
  • the kit may also contain multiple formulations of different active agents.
  • kits will also typically include means for packaging the individual kit components, i.e., the pharmaceutical dosage forms, the administration device (if included), and the written instructions for use.
  • packaging means may take the form of a cardboard or paper box, a plastic or foil pouch, etc.
  • a cream formulation is prepared for the topical administration of VIP.
  • the cream includes the following components: VIP 750 mg Beeswax 2.7 g Carbopol ® 934 q.s. 100.0 g
  • Example 1 The procedure of Example 1 is repeated except that the following components are used: Stearyl-VIP 500 mg Polyethylene glycol 400 37.5 g 1,2,6-hexanetriol 20.0 g Polyethylene glycol 4000 q.s. 100.0 g
  • Stearyl-VIP is prepared as described in U.S. Pat. No. 5,147,855 to Gozes et al. A homogenous cream mixture is obtained.
  • Example 1 The procedure of Example 1 is repeated except that the following components are used: Stearyl VIP 7-28 750 mg Polyethylene glycol 400 37.0 g Polyethylene glycol 400 monostearate 26.0 g Polyethylene glycol 4000 q.s. 100.0 g
  • Stearyl-VIP is prepared as described in U.S. Pat. No. 5,147,855 to Gozes et al. A homogenous cream mixture is obtained.
  • Example 1 The procedure of Example 1 is repeated except that the following components are used: VIP-Gly-Cys-NH 2 (SEQ. ID NO.: 204) 750 mg Polyethylene glycol 400 47.5 g Cetyl Alcohol 5.0 g Polyethylene glycol 4000 q.s. 100.0 g
  • VIP-Gly-Cys-NH 2 (SEQ. ID NO.: 204) is prepared as described in U.S. Pat. No. 5,612,314 to Stamler et al. A homogenous cream mixture is obtained.
  • Example 1 The procedure of Example 1 is repeated except that the following components are used: VIP-Gly-Cys-NO (SEQ. ID NO.: 203) 750 mg Polyethylene glycol 400 47.5 g Cetyl Alcohol 5.0 g Polyethylene glycol 4000 q.s. 100.0 g
  • VIP-Gly-Cys-NO (SEQ. ID NO.: 203) is prepared as described in U.S. Pat. No. 5,612,314 to Stamler et al. A homogenous cream mixture is obtained.
  • An ointment formulation is prepared for the topical administration of VIP.
  • the ointment includes the following components: VIP 750 mg Anhydrous lanolin 20.0 g Mineral oil 25.0 g White Petrolatum q.s. 100.0 g
  • Example 5 The procedure of Example 5 is repeated except that the following components are used: VIP 750 m Diisopropyl Adipate 19.95 g White Petrolatum, USP q.s. 100.0 g
  • optional ingredients can include materials such as antioxidants, viscosity modifiers (e.g., paraffin wax or lanolin wax), and topical absorption rate modifiers.
  • materials such as antioxidants, viscosity modifiers (e.g., paraffin wax or lanolin wax), and topical absorption rate modifiers.
  • a vaginal suppository formulation is prepared using a synthetic or semisynthetic prostaglandin.
  • the suppository includes the following components: Prostaglandin 0.25 gm Polyethylene glycol 400 37.0 gm Glycerol gelatin 20.0 gm Polyethylene glycol 4000 q.s. 100.0 gm
  • polyethylene glycol 400 solution containing prostaglandin is mixed well with glycerol gelatin or similar suppository base such as macrogol, Witepsol®, or the like, with a mechanical mixing apparatus, and the mixture is then cooled in a suppository mold.
  • Suppositories suitable for vaginal administration of a unit dosage of VIP are made as follows. Twenty mg VIP are mixing the selected prostaglandin with 250 mg polyethylene glycol, molecular weight (M w ) approximately 4000, and the mixture is heated to a temperature just high enough to produce a melt. The melted mixture is then poured into a mold suitable to provide a suppository, and allowed to cool. The suppository so provided is a unit dosage form suitable for vaginal administration.
  • compositions prepared in Examples 1-9, formulated with VIP or an analog thereof, are each assessed in the experimental subjects for their ability to increase uterine or vaginal epithelial blood flow.
  • the formulations are applied vaginally and to the vulvar region, and changes in blood flow and/or vaginal fluid production after application of the vasodilating formulations are determined using known methods.
  • Increase in vaginal epithelial blood flow is determined using indirect methods such as photoplethysmography (Levin (1980) Clinics in Obstet. Gynaecol. 7:213-252), heated oxygen electrode (Wagner et al.
  • vaginal dryness and/or dyspareunia are negatively correlated with vaginal blood flow rates, wherein increased blood flow to the vagina correlates with increased lubrication and decreased frequency and severity of dyspareunia (Sarrel, P. M. (1990) Obstet. Gynaecol. 75:26S-32S). Accordingly, vulvar blood flow after treatment is assessed using laser Doppler velocimetry and compared to baseline levels. Increased vaginal lubrication as a result of treatment with the vasoactive formulations can also be assessed using the methods of Semmens et al. (1982) J. Am. Med. Assoc. 248:445-448. The compositions of Examples 1-9, when assessed using such methods, are found to substantially increase blood flow to the vagina and vulvar area and alleviate vaginal dryness.

Abstract

Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal polypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation-in-part of U.S. patent application Ser. No. 09/498,522, filed Feb. 4, 2000, which is a divisional of U.S. patent application Ser. No. 09/181,316, filed Oct. 27, 1998, abandoned, which was a continuation-in-part of U.S. patent application Ser. No. 08/959,064, filed Oct. 28, 1997, which issued on Mar. 2, 1999 as U.S. Pat. No. 5,877,216, and which was also a continuation-in-part of U.S. patent application Ser. No. 08/959,057, also filed Oct. 28, 1997, now abandoned, the disclosures of which are hereby incorporated by reference.[0001]
    • TECHNICAL FIELD
  • This invention relates generally to methods and pharmaceutical formulations for treating female sexual dysfunction, and more particularly relates to vaginal and/or vulvar administration of a vasoactive agent, such as a prostaglandin or a vasoactive intestinal polypeptide, in such treatment. The invention further relates to additional methods of using the present pharmaceutical formulations, including, but not limited to, the prevention of yeast infections and the improvement of vaginal muscle tone. [0002]
    • BACKGROUND
  • Sexual response in women is generally classified into four stages: excitement, plateau, orgasm, and resolution. Masters and Johnson, [0003] Human Sexual Response (Boston, Mass.: Little, Brown & Co., 1966). With sexual arousal and excitement, vasocongestion and muscular tension increase progressively, primarily in the genitals, and is manifested by increased blood flow, elevated luminal oxygen tension, and vaginal surface lubrication as a result of plasma transudation that saturates the fluid reabsorptive capacity of the vaginal epithelium. Vasoactive intestinal polypeptide (“VIP”) release may induce the physiological changes of sexual arousal and excitement, and may be the major neurotransmitter effecting neurologically controlled increase of the vaginal blood supply upon arousal. The peptide histidine methionine has been co-located with VIP within nerve fibers that innervate small blood vessels, smooth muscle and epithelial cells in the vaginal tract.
  • VIP is a neurotransmitter known to effect small vessel dilation in the mesenteric blood supply in response to mechanical sensation of food in the gut to promote digestion. VIP is therefore found in the cholinergic, parasympathetic ganglia of the intestinal peripheral nervous system. Kandel, Schwartz and Jessel, [0004] Principles of Neural Science, 4th Ed. (McGraw-Hill 2000). VIP was initially discovered, isolated and purified from porcine intestine, and the twenty-eight (28) amino acid VIP has extensive homology to secretin and glucagon (Carlquist et al. (1982) Horm. Metab. Res. 14:28-29). VIP is known to exhibit a wide range of biological activities in the gastrointestinal tract and circulatory system. VIP has been shown to stimulate pancreatic and biliary secretion, hepatic glycogenolysis, glucagon and insulin secretion and to activate pancreatic bicarbonate release (Kerrins t al. (1972) Proc. Soc. Exp. Biol. Med. 142:1014-1017; Domschke et al. (1977) Gastroenterology 73:78-480).
  • The physiologic effects of VIP extend outside the digestive system. For example, neurons containing VIP have been localized by immunoassay in cells of the endocrine and exocrine systems, intestine and smooth muscle (Polak et al. (1974) [0005] Gut 15:720-724), and has been found to be a neuroeffector of the release of hormones including prolactin (Frawley et al. (1981) Neuroendocrinology 33:79-83), thyroxine (Ahren et al. (1980) Nature 287:343-345), and the aforementioned insulin and glucagon (Schebalin, et al. (1977) Am. J. Physiology E. 232:197-200. VIP is present in neurons and neural junctions in the airways of animal species including man (Dey et al. (1980) Fed. Proc. 39:1062; Said et al. (1974) Ann. N.Y. Acad. Sciences 221:103-114). VIP has also been found to stimulate renin release from the kidney in vivo and in vitro (Porter et al. (1983) Neuroendocrinology 36:404-408), and the presence of VIP in other parts of the genito-urinary system has been shown. The widely appreciated direct vasoactive effect of VIP is to increase blood flow into capillary bed by dilation of the afferent blood vessel. Various analogs of VIP, both agonistic and antagonistic are known to exist (see for example U.S. Pat. Nos. 5,235,907, 5,141,924, 4,734,400 and 4,605,641 to Bolin; and U.S. Pat. Nos. 4,939,224 and 4,835,252 to Musso et al.).
  • Sexual excitement is initiated by any of a number of psychogenic or somatogenic stimuli and must be reinforced to result in orgasm. With continued stimulation, excitement progresses in intensity into a plateau stage, from which the individual can shift into orgasm. The orgasmic stage is characterized by a rapid release from vasocongestion and muscular tension. [0006]
  • During the various stages of sexual response, characteristic genital and extragenital responses occur. Estrogens magnify the sexual responses; however, sexual responses may also occur in estrogen-deficient individuals. Sexual dysfunction may be due to organic or functional disturbances. For example, a variety of diseases affecting neurologic function, including diabetes mellitus and multiple sclerosis, may interrupt sexual arousal. More commonly, local pelvic disorders, such as endometriosis and vaginitis, both of which cause dyspareunia (difficult or painful coitus) may also affect a woman's sexual response. In addition, estrogen deficiency, causing vaginal atrophy and dyspareunia, is a common cause of sexual dysfunction. For a discussion of other causes of female sexual dysfunction, see, e.g., Kaplan, [0007] The Evaluation of Sexual Disorders: Psychological and Medical Aspects (New York, N.Y.: Brunner-Mazel, 1983), and Kolodny et al., Textbook of Sexual Medicine (Boston, Mass.: Little, Brown & Co., 1979).
  • Excitement stage dysfunction generally involves touch sensation impairment, loss of clitoral sensation, vaginal dryness and urinary incontinence. Such excitement phase dysfunction generally results in dyspareunia. Dyspareunia is thought to affect approximately 40% of women, due in large part to inadequate lubrication. It has been estimated that over 40 million women will suffer dyspareunia at some time in their lives. On the order of twenty-five million women will experience dyspareunia in the peri- and postmenopausal period (see Kelly, S. (1992) [0008] Clinical Practice and Sexuality 8(8):2 and Sato et al. (1992) Clinical Practices in Sexuality 8(5):1). Contemporary symptomatic treatments generally involve the use of physiologically safe lubricants such as egg white, K-Y surgical lubrication jelly (hydroxyethyl-cellulose), Astroglide7, and Replens7. See, for example, Semmens (1974) Medical Aspects of Human Sexuality 8:85-86, and Frishmen et al. (1992) Fertility and Sterility 8(3):630. When symptomatic treatment fails, pharmacological treatment may be indicated.
  • Estrogen therapy is commonly used in the pharmacological treatment of sexual dysfunction in women. Estrogen-based therapies are generally used to increase mucous production, provide vasodilatory effects, or to increase the general health of the vagina. Nadelson et al., eds., [0009] Treatment Interventions in Human Sexuality (New York: Plenum Press, 1983). In such treatments, estrogen is administered orally, parenterally (e.g., by injection), or topically. With oral administration, the estrogen concentration encountered by the liver is generally four- to five-fold greater than estrogen levels in peripheral blood (the “first pass effect”). This effect may lead to an undesirable increase in the production of certain coagulation factors and renin substrates by the liver. Parenterally administered estrogen avoids the first pass effect in the liver. However, all estrogen-based therapies are known to increase the risk of endometrial hyperplasia, endometrial cancer and breast cancer in treated individuals.
  • Because of the increased risk of endometrial hyperplasia and endometrial cancer encountered with unopposed estrogen therapies, estrogen/progestogen combinations have been employed. However, progestogens are known to have some androgenic activity. Further, common side effects from such therapies include uterine bleeding and the continuation of menstrual periods. Accordingly, there remains a need in the art to provide safer and more ways of treating female sexual dysfunction. [0010]
  • The present invention is directed to the aforementioned need in the art, and provides a new, highly effective method of treating sexual dysfunction in women. The method involves vaginal and/or vulvar administration of a pharmaceutical formulation containing a vasoactive agent, e.g., a prostaglandin, VIP or a VIP agonist or the like. [0011]
  • Drug therapy for treating female sexual dysfunction has been described. For example, U.S. Pat. No. 4,507,323 to Stern describes the use of the anxiolytic m-chloro-α-t-butylamino-propiophenone in the treatment of sexual dysfunction in both male and female individuals. Pharmaceutical compositions containing the agent are described, which are presented in discrete units, e.g., cachets, tablets, capsules, ampules and suppositories, for oral or rectal delivery of the agent. [0012]
  • Additionally, U.S. Pat. No. 4,521,421 to Foreman describes the treatment of sexual dysfunction in male and female individuals using the stereoisomers of octahydropyrimido[4,5-g]quinolines, centrally acting dopamine agonists. [0013]
  • U.S. Pat. No. 5,190,967 to Riley describes the treatment of sexual disorders in male and female individuals using heterocyclic benzodioxinopyrrole compounds, which, like the drugs described in the aforementioned patents, are centrally acting agents. [0014]
  • U.S. Pat. Nos. 5,565,466 to Gioco et al., 5,731,339 to Lowrey, and 5,773,457 to Nahoum pertain to methods for modulating the human sexual response, with the Gioco et al. and Lowrey patents emphasizing the utility of phentolarnine as an active agent. [0015]
  • A number of references describe various methods and devices suitable for vaginal or uterine drug administration, and may accordingly be of some interest with respect to the present invention. The following are representative of such references: [0016]
  • U.S. Pat. No. 3,967,618 to Zaffaroni describes an intrauterine device adapted for drug delivery. A number of drugs are mentioned as being suitable for use in conjunction with the device. However, the patent does not mention treatment of sexual dysfunction, nor is application of a drug-containing composition to the clitoris or vulvar region disclosed or suggested. U.S. Pat. No. 3,948,254 to Zaffaroni is a related patent that describes an intrauterine device for continuous administration of a contraceptive agent. [0017]
  • U.S. Pat. No. 4,014,987 to Heller et al. describes a tampon-like device for delivery of a drug to the uterus or vagina. Heller et al. mention that delivery of prostaglandins is a preferred use of the invention; however, there is no disclosure concerning treatment of sexual dysfunction or delivery to the vulvar area or urethra. [0018]
  • U.S. Pat. No. 4,564,362 to Burnhill describes a vaginal sponge for controlled release of a contraceptive agent. [0019]
  • U.S. Pat. No. 4,112,942 to Scaife generally describes vaginal administration of medicinal foams. [0020]
  • There are, accordingly, a number of background references relating to treatment of female sexual dysfunction, and cervical or uterine administration of vasoactive agents. However, the present method for treating female sexual dysfunction, by way of vaginal and/or vulvar delivery of a vasoactive agent such as a prostaglandin or VIP or a receptor agonist thereof, is completely novel and unsuggested by the art. [0021]
    • SUMMARY OF THE INVENTION
  • Accordingly, it is a primary object of the invention to provide a method for treating sexual dysfunction in a female individual by administering a pharmaceutical formulation containing a selected vasoactive agent to the vaginal and/or vulvar area of the individual undergoing treatment. [0022]
  • It is still another object of the invention to provide methods for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, preventing vaginal atrophy, preventing pain during intercourse as a result of dyspareunia, alleviating vaginal itching and dryness associated with dyspareunia and other conditions, and minimizing collagen misdeposition resulting from hypoxia, each of such methods vaginal and/or vulvar administration of a pharmaceutical formulation containing a selected vasoactive agent, in combination with a pharmaceutically acceptable vehicle. [0023]
  • It is an additional object of the invention to provide such methods wherein the vasoactive agent is vasoactive intestinal polypeptide or an agonist thereof. [0024]
  • It is still an additional object of the invention to provide such methods wherein drug administration is carried out on an as-needed basis. [0025]
  • It is a further object of the invention to provide pharmaceutical formulations useful in conjunction with the aforementioned methods. [0026]
  • Additional objects, advantages and novel features of the invention will be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention. [0027]
  • In one aspect of the invention, then, a method is provided for treating sexual dysfunction in a female individual comprising administering to the vagina and/or vulvar area a pharmaceutical formulation containing a selected vasoactive agent. The vasoactive agent is preferably a vasodilator, with preferred vasodilators selected from the group consisting of VIP and vasoactive intestinal polypeptide agonists, both natural and synthetic, and combinations of any of the foregoing. Any number of drug delivery platforms may be used, e.g., suppositories, ointments, creams, gels, solutions and the like, which will be described in detail below. Also, one or more additional types of drugs, i.e., pharmacologically active agents other than vasoactive agents, may be incorporated into the pharmaceutical formulations. In other aspects of the invention, vaginal administration of a vasoactive agent as just described is used to improve vaginal muscle tone and tissue health, to enhance vaginal lubrication, or to minimize collagen misdeposition resulting from hypoxia as well as the associated lack of elasticity resulting from the collagen misdeposition. [0028]
  • In another aspect of the invention, pharmaceutical compositions and dosage forms are provided for carrying out the aforementioned methods. The compositions and dosage forms contain a vasoactive agent as described above, a pharmaceutically acceptable vehicle, and, optionally, one or more additional pharmacologically active agents. The formulations contain a therapeutically effective amount of the active agent, or a therapeutically effective concentration of the active agent, i.e., a concentration that provides a therapeutically effective amount of active agent upon administration of a selected volume of composition. [0029]
  • In another embodiment, packaged kits are provided for individuals to carry out the aforementioned methods. Packaged kits include a pharmaceutical composition or dosage form containing the active agent, a container housing the composition or dosage form during storage and prior to administration, and instructions, e.g., written instructions on a package insert or label, for carrying out drug administration in a therapeutically effective manner. The composition or dosage form may be any of those described herein. [0030]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Before describing the present invention in detail, it is to be understood that this invention is not limited to delivery of specific drugs, carriers or use of particular drug delivery systems, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. [0031]
  • It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a vasoactive agent” includes a mixture of two or more vasoactive agents, reference to “a pharmaceutically acceptable excipient” includes mixtures of such excipients, and the like. [0032]
  • In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below. [0033]
  • The terms “active agent,” “pharmacologically active agent” and “drug” are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological, physiological effect, i.e., in this case, enhancement of female sexual desire and responsiveness. The primary active agents herein are vasoactive intestinal polypeptide and agonists thereof. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, and the like. When the terms “active agent,” “pharmacologically active agent” and “drug” are used, then, it is to be understood that applicants intend to include the active agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, metabolites, analogs, etc. [0034]
  • The pharmacologically active agents herein are vasoactive intestinal polypeptide and analogs thereof that serve as VIP agonists. [0035]
  • By “pharmaceutically acceptable,” such as in the recitation of a “pharmaceutically acceptable carrier,” or a “pharmaceutically acceptable acid addition salt,” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. “Pharmacologically active” (or simply “active”) as in a “pharmacologically active” derivative or metabolite, refers to a derivative or metabolite having the same type of pharmacological activity as the parent compound and approximately equivalent in degree. When the term “pharmaceutically acceptable” is used to refer to a derivative (e.g., a salt) of an active agent, it is to be understood that the compound is pharmacologically active as well, i.e., therapeutically effective to enhance female sexual desire and responsiveness. [0036]
  • “Carriers” or “vehicles” as used herein refer to conventional pharmaceutically acceptable carrier materials suitable for drug administration, and include any such materials known in the art that are nontoxic and do not interact with other components of a pharmaceutical composition or drug delivery system in a deleterious manner. [0037]
  • By an “effective” amount or a “therapeutically effective amount” of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect, i.e., treatment of female sexual dysfunction. The amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. [0038]
  • The terms “treating” and “treatment” as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. Thus, for example, “treating” sexual dysfunction, as the term is used herein, encompasses both prevention of sexual dysfunction in clinically asymptomatic individuals and treatment of dysfunction in a clinically symptomatic individual. [0039]
  • By “treating female sexual dysfunction” is meant enhancing female sexual desire and responsiveness. Applicants intend to include the treatment of disorders of female sexual desire and/or response, meaning any disorder or dysfunction that causes a decrease in or absence of female sexual responsiveness or female sexual desire. This includes any persistent or recurrent deficiency in the desire for sexual activity. It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the female erectile tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of or pleasure in orgasms: frigidity; sexual aversion; and disorders of female sexual desire and response that are secondary to a general medical condition such as the menopausal or post-menopausal state, radiotherapy of the pelvis, atherosclerosis, pelvic trauma or surgery, peripheral neuropathies, autonomic neuropathies, diabetes mellitus, and disorders of the innervation of any of the sexual organs. This term also includes substance-induced sexual dysfunction, including but not limited to, decreases in desire and responsiveness secondary to anti-depressants, neuroleptics, anti-hypertensives, tobacco, opiates, alcohol and any other drug found to decrease or eliminate any part of the sexual response cycle. Primary and secondary anorgasmia are included. [0040]
  • By “as-needed” dosing, also referred to as “pro re nata” dosing, “pm” dosing, and “on-demand” dosing or administration, is meant the administration of an active agent at a time just prior to the time at which drug efficacy is wanted, e.g., just prior to anticipated sexual activity, and within a time interval sufficient to provide for the desired therapeutic effect, i.e., enhancement in sexual desire and in sexual responsiveness during sexual activity. “As-needed” administration herein does not involve priming doses or chronic administration, “chronic” meaning administration at regular time intervals on an ongoing basis. As-needed administration may involve administration immediately prior to sexual activity, but will generally be about 0.25 to 72 hours, preferably about 0.5 to 48 hours, more preferably about 1 to 24 hours, most preferably about 1 to 12 hours, and optimally about 1 to 4 hours prior to anticipated sexual activity. “As-needed” administration may or may not involve administration of a sustained release formulation in advance of anticipated sexual activity, with drug release taking place throughout an extended drug delivery period typically in the range of about 4 to 72 hours. [0041]
  • The term “controlled release” is intended to refer to any drug-containing formulation in which release of the drug is not immediate, i.e., with a “controlled release” formulation, oral administration does not result in immediate release of the drug into an absorption pool. The term is used interchangeably with “nonimmediate release” as defined in Remington: [0042] The Science and Practice of Pharmacy, Nineteenth Ed. (Easton, Pa.: Mack Publishing Company, 1995). As discussed therein, immediate and nonimmediate release can be defined kinetically by reference to the following equation:
    Figure US20020099003A1-20020725-C00001
  • The “absorption pool” represents a solution of the drug administered at a particular absorption site, and k[0043] r, ka and ke are first-order rate constants for (1) release of the drug from the formulation, (2) absorption, and (3) elimination, respectively. For immediate release dosage forms, the rate constant for drug release kr is far greater than the absorption rate constant ka. For controlled release formulations, the opposite is true, i.e., kr<<ka, such that the rate of release of drug from the dosage form is the rate-limiting step in the delivery of the drug to the target area. The term “controlled release” as used herein includes any nonimmediate release formulation, including but not limited to sustained release, delayed release and pulsatile release formulations.
  • The term “sustained release” is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period. A sustained release formulation may be administered once to provide a single bolus dose of the active agent, which is then effective for up to a day or even up to several days. [0044]
  • By the term “transdermal” drug delivery is meant delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream. [0045]
  • The term “topical administration” is used in its conventional sense to mean delivery of a topical drug or pharmacologically active agent to the skin or mucosa. Topical administration thus includes transmucosal administration. [0046]
  • Generally, “vaginal delivery” of a pharmaceutical formulation involves administration to the distal several centimeters of the vagina. The terms “vulvar delivery” and “vulvar administration” are used herein to refer to application of a pharmaceutical formulation to the vulvar area of an individual undergoing treatment. The term is intended to encompass application to the clitoris as well as the surrounding vulvar area. The terms “vulvar delivery” and “clitoral delivery” are used interchangeably herein and are both intended to refer to administration to the vulvar area of the individual undergoing treatment. [0047]
  • In order to carry out the method of the invention, VIP or an agonist thereof is administered to the vagina and/or vulvar region of a female individual to enhance sexual desire and responsiveness; the individual may or may not be suffering from a sexual disorder or dysfunction. The active agent is administered locally and transmucosally, i.e., vaginally and/or to the vulvar region. [0048]
  • As used herein, the term “C[0049] 1-3 alkyl” refers to methyl, ethyl, propyl, and isopropyl.
  • The nomenclature used to define the vasoactive intestinal peptides of the invention is that typically used in the art, wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right. By natural amino acids is meant one of the naturally occurring amino acids found in proteins, i.e., Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp, and His. By Nle is meant norleucine. By Orn is meant ornithine. By Ac is meant acetyl (CH[0050] 3CO2). Where the amino acid has isomeric forms, it is the L form of the amino acid that is represented unless otherwise expressly indicated.
  • Analogs of VIP, i.e., those analogs included herein as VIP agonists, are indicated by setting forth the substituted amino acid in brackets before “VIP.” Derivatization of the N-terminal amino group is indicated to the left of the bracketed substitutions. Sequence numbers appearing in parentheses to the right of “VIP” indicate amino acid deletions and additions to the native sequence numbering. That is, for example, Ac-[Lys[0051] 12,Nle17,Gly29]-VIP(2-29) indicates a polypeptide having an amino acid sequence corresponding to native human VIP in which an acetyl group has been substituted for hydrogen at the N-terminus, lysine has been substituted for arginine at position 12 and norleucine has been substituted for methionine at position 17, the histidine at position 1 has been deleted and a glycine has been coupled onto the carboxyl side of asparagine 28, termed position 29. The suffixes “—OH” and “—NH2” following “VIP” refer to the free acid and amide forms of the polypeptide, respectively. In the event neither suffix is used, the expression is intended to encompass both forms.
  • The following abbreviations are also defined: N—CH[0052] 3-Ala is N-methyl-alanine, p-F-Phe is fluoro-phenylalanine, 1-Nal is 3-(1′-naphthyl)-alanine, 2-Nal is 3-(2′-naphthyl)-alanine, p-NH2-Phe is p-amino-phenylalanine, O—CH3-Tyr is O-methyl-tyrosine, Cys(Acm) is S-acetoamidomethyl-cysteine, m-F-Tyr is m-fluoro-tyrosine.
  • In a first embodiment, the invention relates to a method for treating sexual dysfunction in a female individual and involves vaginal and/or vulvar administration of a pharmaceutical formulation containing a vasoactive agent, preferably a vasodilator. Preferred vasodilators are selected from the group consisting of vasoactive intestinal polypeptide, VIP agonists, pharmaceutically acceptable salts, esters, derivatives, prodrugs, and inclusion complexes thereof, and combinations of any of the foregoing, in combination with a pharmaceutically acceptable vehicle. [0053]
  • VIP agonists are, as noted above, useful for practicing the invention. The sequence of human VIP, which is the same as rat, bovine and porcine VIP is known to be: [0054]
  • His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn. [0055]
  • In the conventional single letter amino acid code the VIP amino acid sequence is: H-S-D-A-V-F-T-D-N-Y-T-R-L-R-K-Q-M-A-V-K-K-Y-L-N-S-I-L-N (SEQ. ID. NO.: 1). VIP sequences from other species are known to exhibit homology to human VIP and therefore expected to exhibit VIP agonistic and/or antagonistic activity. Partial agonists of VIP that are also antagonists of VIP, for example agonists that are less active than endogenously secreted VIP may be used in the methods of the invention depending upon activity relative to physiologic human VIP and local dosage. The usefulness of partial VIP agonists for practicing the invention may be ascertained by conventional trials and pharmacologic assays known in the art. [0056]
  • Representative vasoactive intestinal polypeptide analogs include peptides having the following amino acid sequences: [0057]
  • [Lys[0058] 12, Nle17]-VIP (SEQ. ID. NO.: 2);
  • Ac-[Lys[0059] 12, Nle17]-VIP (SEQ. ID. NO.: 3);
  • [Orn[0060] 12, Nle17]-VIP (SEQ. ID. NO.: 4);
  • Ac-[Orn[0061] 12, Nle17]-VIP (SEQ. ID. NO.: 5);
  • [Ser[0062] 11,Phe13,Nle17]-VIP (SEQ. ID. NO.: 6);
  • Ac-[Ser[0063] 11,Phe13,Nle17]-VIP (SEQ. ID. NO.: 7);
  • [Nle[0064] 17,Thr25]-VIP (SEQ. ID. NO.: 8);
  • [Nle[0065] 17,Thr24]-VIP (SEQ. ID. NO.: 9);
  • [Ala[0066] 9,Nle17]-VIP (SEQ. ID. NO.: 10);
  • Ac-[Ala[0067] 9,Nle17]-VIP (SEQ. ID. NO.: 11);
  • [Lys[0068] 14,Nle17]-VIP (SEQ. ID. NO.: 12);
  • [Nle[0069] 17,Val26,Thr28]-VIP (SEQ. ID. NO.: 13);
  • [Lys[0070] 12,Lys14,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 14);
  • [Nle[0071] 17,Thr28]-VIP (SEQ. ID. NO.: 15);
  • Ac-[Nle[0072] 17,Thr28]-VIP (SEQ. ID. NO.: 16);
  • [Lys[0073] 12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 17);
  • Ac-[Orn[0074] 12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 18);
  • Ac-[Lys[0075] 12,Lys14,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 19);
  • Ac-[Lys[0076] 12,Nle17,Thr25,Val26,Thr28]-VIP (SEQ. ID. NO.: 20);
  • Ac-[Lys[0077] 12,Nle17,Val26,Ala28]-VIP;
  • Ac-[Lys[0078] 12,Nle17,Val26,Ala27,Thr28]-VIP (SEQ. ID. NO.: 21);
  • Ac-[Lys[0079] 12,Nle17,Ala26,Thr28]-VIP (SEQ. ID. NO.: 22);
  • Ac-[Lys[0080] 12,Nle17,Ala25,Val26,Thr28]-VIP (SEQ. ID. NO.: 23);
  • Ac-[Lys[0081] 12,Nle17,Ala24,Val26,Thr28]-VIP (SEQ. ID. NO.: 24);
  • Ac-[Lys[0082] 12,Nle17,Ala23,Val26,Thr28]-VIP (SEQ. ID. NO.: 25);
  • Ac-[Lys[0083] 12,Nle17,Ala22,Val26,Thr28]-VIP (SEQ. ID. NO.: 26);
  • Ac-[Lys[0084] 12,Nle17,Ala21,Val26,Thr28]-VIP (SEQ. ID. NO.: 27);
  • Ac-[Lys[0085] 12,Nle17,Ala20,Val26,Thr28]-VIP (SEQ. ID. NO.: 28);
  • Ac-[Lys[0086] 12,Nle17,Ala19,Val26,Thr28]-VIP (SEQ. ID. NO.: 29);
  • Ac-[Lys[0087] 12,Ala17,Val26,Thr28]-VIP (SEQ. ID. NO.: 30);
  • Ac-[Lys[0088] 12,Ala16,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 31);
  • Ac-[Lys[0089] 12,Ala15,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 32);
  • Ac-[Lys[0090] 12,Ala14,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 33);
  • Ac-[Lys[0091] 12,Ala13,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 34);
  • Ac-[Ala[0092] 12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 35);
  • Ac-[Ala[0093] 11,Lys12,Nle17,Val26Thr28]-VIP (SEQ. ID. NO.: 36);
  • Ac-[Ala[0094] 10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 37);
  • Ac-[Ala[0095] 9,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 38);
  • Ac-[Ala[0096] 8,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 39);
  • Ac-[Ala[0097] 7,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 40);
  • Ac-[Ala[0098] 6,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 41);
  • Ac-[Ala[0099] 5,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 42);
  • Ac-[Ala[0100] 3,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 43);
  • Ac-[Ala[0101] 2,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 44);
  • Ac-[Ala[0102] 1,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 45);
  • Ac-[Gly[0103] 1,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 46);
  • Ac-[Leu[0104] 5,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 47);
  • Ac-[1-Nal[0105] 6,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 48);
  • Ac-[p-F-Phe[0106] 6,Lys12,Nle17,Val 26,Thr28]-VIP (SEQ. ID. NO.: 49);
  • Ac-[Glu[0107] 8,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 50);
  • Ac-[2 -Nal[0108] 10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 51);
  • Ac-[p-NH[0109] 2-Phe10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 52);
  • Ac-[O—CH[0110] 3-Tyr10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 53);
  • Ac-[Lys[0111] 12 Nle17,m-F-Tyr22,Val26,Thr28]-VIP (SEQ. ID. NO.: 54);
  • Ac-[Lys[0112] 12,Nle17,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 55)
  • Ac-[Lys[0113] 12,Nle17,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 56);
  • Ac-[Lys[0114] 12,Nle17,Val26,Thr28,Gly29,30,Thr31]-VIP (SEQ. ID. NO.: 57);
  • Ac-[Lys[0115] 12,Nle17,Val26,Thr28,Ala29,30,Met31]-VIP (SEQ. ID. NO.: 58);
  • Ac-[Lys[0116] 12,Nle17,Val26,Thr28,Ala29-31]-VIP (SEQ. ID. NO.: 59);
  • Ac-[Lys[0117] 12,Nle17,Val26,Thr28,Gly29,Lys30]-VIP (SEQ. ID. NO.: 60);
  • Ac-[Lys[0118] 12, 14,Nle17,Ala19,Val26,Thr28]-VIP (SEQ. ID. NO.: 61);
  • Ac-[2-Nal[0119] 10,Lys12,Ala17,Val26,Thr28]-VIP (SEQ. ID. NO.:62);
  • Ac-[Glu[0120] 8,Lys12,Nle17,Val26,Thr28,Ala29,30,Met31]-VIP (SEQ. ID. NO.: 63);
  • Ac-[Glu[0121] 8,Lys12,Nle17,Val26,Thr28,Phe31]-VIP (SEQ. ID. NO.:64);
  • Ac-[p-F-Phe[0122] 6,Glu8,Lys12,Nle17,Ala19,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 65);
  • Ac-[p-F-Phe[0123] 6,p-NH2-Phe10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 66);
  • Ac-[Lys[0124] 12,Ala17,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 67);
  • Ac-[Glu[0125] 8,Lys12,14,Nle17,Val26, Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 68);
  • Ac-[p-NH[0126] 2-Phe10,Lys12,Nle17,Ala19,Val26,Thr28]-VIP (SEQ. ID. NO.: 69);
  • Ac-[p-F-Phe[0127] 6,Glu8,Lys12,Nle17,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 70);
  • Ac-[Glu[0128] 8,Lys12 Ala17,19,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 71);
  • Ac-[Glu[0129] 8Lys12,Nle17,Val26 Thr28,Gly29,30,Ala31]-VIP (SEQ. ID. NO.: 72);
  • Ac-[Glu[0130] 8,Lys12,Nle17,Ala19,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 73);
  • Ac-[p-F-Phe[0131] 6,Lys12,Nle17,Ala19,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 74);
  • Ac-[Glu[0132] 8,Lys12,Nle17,Val26,Thr28,Gly29,30,Ser31]-VIP (SEQ. ID. NO.: 75);
  • Ac-[p-F-Phe[0133] 6,Glu8,Lys12,Nle17,Ala19,Val26,Thr28]-VIP (SEQ. ID. NO.: 76);
  • Ac-[Glu[0134] 8,Orn12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 77);
  • Ac-[Lys[0135] 12Nle17,Ala25,Leu26Lys27,28,Gly29,30,Thr31]-VIP (SEQ. ID. NO.: 78);
  • Ac-[Glu[0136] 8,Lys12,Nle7,Val26,Thr28,Ala29-31]-VIP (SEQ. ID. NO.: 79);
  • Ac [Lys[0137] 12,Ala17,19,Val26,Thr28]-VIP (SEQ. ID. NO.: 80);
  • Ac-[Glu[0138] 8,Lys12,Nle17,Val26,Thr28,Gly29,Lys30]-VIP (SEQ. ID. NO.: 81);
  • Ac-[p-HN[0139] 2-Phe10,Lys12,Nle17,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 82);
  • Ac-[Glu[0140] 8,Lys12,Nle17,Val26,Thr28,Gly29,30,Cys (Acm)31]-VIP (SEQ. ID. NO.: 83);
  • Ac-[Glu[0141] 8,Lys12,Nle17,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 84);
  • CH[0142] 3S(CH2)2CO-[Lys12,Nle17,Val26,Thr28]-VIP(2-28) (SEQ. ID. NO.: 85);
  • CH[0143] 3SO(CH2)2CO-[Lys12,Nle17,Val26,Thr28]-VIP(2-28) (SEQ. ID. NO.: 86);
  • Ac-[N—CH[0144] 3-Ala1,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 87);
  • Ac-[Leu[0145] 5,Orn12,Ala17,19,Thr25,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 88);
  • Ac-[p-F-Phe[0146] 6, 2-Nal10,Lys12,Nle17,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 89);
  • Ac-[p-F-Phe[0147] 6,Glu8,Lys12,14,Nle17,Ala19,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 90).
  • Particularly common vasoactive intestinal polypeptide analogs known in the art include the following: [0148]
  • Ac-[p-F-Phe[0149] 6,Lys12,Nle17Ala19,Val26,Thr28Gly29,30Cys(Acm)31]-VIP (SEQ. ID. NO.: 91);
  • Ac-[Leu[0150] 5,Orn12,Ala17 Thr25,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 92);
  • Ac-[p-F-Phe[0151] 6,Glu8,Lys12,Nle17,Ala19,Val26,Thr28,Gly29,30,Cys(Acm)31]-VIP (SEQ. ID. NO.: 93);
  • Ac-[N-Me-Ala[0152] 1,Lys12Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 94);
  • Ac-[p-F-Phe[0153] 6,p-NH2-Phe10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 95);
  • Ac-[Glu[0154] 8 Lys12,Nle17,Val26,Thr28,Gly29,30,Met31]-VIP (SEQ. ID. NO.: 96);
  • Ac-[p-NH[0155] 2-Phe10,Lys12,Nle17,Val26,Thr28]-VIP (SEQ. ID. NO.: 97);
  • Ac-[Glu[0156] 8,Lys12,Nle17,Val26,Thr28,Gly29,30,Cys (Acm)31]-VIP (SEQ. ID. NO.: 98).
  • Other VIP analogs known in the art include: [0157]
  • [Nle.sup.[0158] 17]-VIP (SEQ. ID. NO.: 99);
  • Ac-[Nle.sup.[0159] 17]-VIP (SEQ. ID. NO.: 100);
  • [Tyr[0160] 6]-VIP (SEQ. ID. NO.: 101);
  • [Phe[0161] 22]-VIP (SEQ. ID. NO.: 102);
  • [Ser[0162] 7]-VIP (SEQ. ID. NO.: 103);
  • [Lys[0163] 7]-VIP (SEQ. ID. NO.: 104);
  • [Gln[0164] 7]-VIP (SEQ. ID. NO.: 105);
  • [Asn[0165] 7]-VIP (SEQ. ID. NO.: 106);
  • [Arg[0166] 7]-VIP (SEQ. ID. NO.: 107);
  • [Arg[0167] 9]-VIP (SEQ. ID. NO.: 108);
  • [Gln[0168] 9]-VIP (SEQ. ID. NO.: 109);
  • [Lys[0169] 9]-VIP (SEQ. ID. NO.: 110);
  • [Leu[0170] 9]-VIP (SEQ. ID. NO.: 111);
  • [Ser[0171] 9] (SEQ. ID. NO.: 112);
  • [Thr[0172] 9]-VIP (SEQ. ID. NO.: 113);
  • [Leu[0173] 11]-VIP (SEQ. ID. NO.: 114);
  • [Lys[0174] 11]-VIP (SEQ. ID. NO.: 115);
  • [Asn[0175] 11]-VIP (SEQ. ID. NO.: 116);
  • [Gln[0176] 11]-VIP (SEQ. ID. NO.: 117);
  • [Arg[0177] 11]-VIP (SEQ. ID. NO.: 118);
  • [Thr[0178] 16]-VIP (SEQ. ID. NO.: 119);
  • [Ser[0179] 16]-VIP (SEQ. ID. NO.: 120);
  • [Leu[0180] 16]-VIP (SEQ. ID. NO.: 121);
  • [Lys[0181] 16]-VIP (SEQ. ID. NO.: 122);
  • [Asn[0182] 16]-VIP (SEQ. ID. NO.: 123);
  • [Arg[0183] 16]-VIP (SEQ. ID. NO.: 1243);
  • [Arg[0184] 24]-VIP (SEQ. ID. NO.: 125);
  • [Gln[0185] 24]-VIP (SEQ. ID. NO.: 126);
  • [Lys[0186] 24]-VIP (SEQ. ID. NO.: 127);
  • [Leu[0187] 24]-VIP (SEQ. ID. NO.: 128);
  • [Ser[0188] 24]-VIP (SEQ. ID. NO.: 129);
  • [Ser[0189] 12]-VIP (SEQ. ID. NO.: 130);
  • [Ser[0190] 20]-VIP (SEQ. ID. NO.: 131);
  • [Orn[0191] 20]-VIP (SEQ. ID. NO.: 132);
  • [Arg[0192] 20]-VIP (SEQ. ID. NO.: 133);
  • [Phe[0193] 23]-VIP (SEQ. ID. NO.: 134);
  • [Phe[0194] 26]-VIP (SEQ. ID. NO.: 135);
  • [Tyr[0195] 13]-VIP (SEQ. ID. NO.: 136);
  • [Tyr[0196] 23]-VIP (SEQ. ID. NO.: 137);
  • [Tyr[0197] 26]-VIP (SEQ. ID. NO.: 138);
  • [Leu[0198] 26]-VIP](SEQ. ID. NO.: 139);
  • [Ile[0199] 13]-VIP (SEQ. ID. NO.: 140);
  • [Ile[0200] 23]-VIP (SEQ. ID. NO.: 141);
  • [Val[0201] 13]-VIP (SEQ. ID. NO.: 142);
  • [Val[0202] 23]-VIP (SEQ. ID. NO.: 143);
  • [Nle[0203] 13]-VIP (SEQ. ID. NO.: 144);
  • [Nle[0204] 23]-VIP (SEQ. ID. NO.: 145);
  • [Nle[0205] 26]-VIP (SEQ. ID. NO.: 146);
  • [Arg[0206] 21]-VIP (SEQ. ID. NO.: 147);
  • [Leu[0207] 14]-VIP (SEQ. ID. NO.: 148);
  • [Leu[0208] 21]-VIP (SEQ. ID. NO.: 149);
  • [Orn[0209] 14]-VIP (SEQ. ID. NO.: 150);
  • [Orn[0210] 21]-VIP (SEQ. ID. NO.: 151);
  • [Nle[0211] 14]-VIP (SEQ. ID. NO.: 152);
  • [Nle[0212] 21]-VIP (SEQ. ID. NO.: 153);
  • [Arg[0213] 15]-VIP (SEQ. ID. NO.: 154);
  • [Ser[0214] 15]-VIP (SEQ. ID. NO.: 155);
  • [Gln[0215] 15]-VIP (SEQ. ID. NO.: 156);
  • [Orn[0216] 15]-VIP (SEQ. ID. NO.: 157);
  • [Met[0217] 19]-VIP (SEQ. ID. NO.: 158);
  • [Leu[0218] 17]-VIP (SEQ. ID. NO.: 159);
  • [Leu[0219] 19]-VIP (SEQ. ID. NO.: 160);
  • [Val[0220] 17]-VIP (SEQ. ID. NO.: 161);
  • [Lys[0221] 17]-VIP (SEQ. ID. NO.: 162);
  • [Lys[0222] 19]-VIP (SEQ. ID. NO.: 163);
  • [Ile[0223] 17]-VIP (SEQ. ID. NO.: 164);
  • [Ile[0224] 19]-VIP (SEQ. ID. NO.: 165);
  • [Nle[0225] 19]-VIP (SEQ. ID. NO.: 166);
  • [Leu[0226] 18]-VIP (SEQ. ID. NO.: 167);
  • [Asn[0227] 25]-VIP (SEQ. ID. NO.: 168);
  • [Leu[0228] 25]-VIP (SEQ. ID. NO.: 169);
  • [Gln[0229] 25]-VIP (SEQ. ID. NO.: 170);
  • [Val[0230] 27]-VIP (SEQ. ID. NO.: 171);
  • [Phe[0231] 3]-VIP (SEQ. ID. NO.: 172);
  • [Tyr[0232] 3]-VIP (SEQ. ID. NO.: 173);
  • [Phe[0233] 7]-VIP (SEQ. ID. NO.: 174);
  • [Tyr[0234] 7]-VIP (SEQ. ID. NO.: 175);
  • [Phe[0235] 19]-VIP (SEQ. ID. NO.: 176);
  • [Tyr[0236] 19]-VIP (SEQ. ID. NO.: 177);
  • [Thr[0237] 4]-VIP (SEQ. ID. NO.: 178);
  • [Ser[0238] 4]-VIP (SEQ. ID. NO.: 179);
  • [Asn[0239] 4]-VIP (SEQ. ID. NO.: 180);
  • [Gln[0240] 4]-VIP (SEQ. ID. NO.: 181);
  • [Thr[0241] 6]-VIP (SEQ. ID. NO.: 182);
  • [Ser[0242] 6]-VIP (SEQ. ID. NO.: 183);
  • [Asn[0243] 6]-VIP (SEQ. ID. NO.: 184);
  • [Gln[0244] 6]-VIP (SEQ. ID. NO.: 185);
  • [Ala[0245] 6]-VIP (SEQ. ID. NO.: 186);
  • [Thr[0246] 8]-VIP (SEQ. ID. NO.: 187);
  • [Ser[0247] 8]-VIP (SEQ. ID. NO.: 188);
  • [Asn[0248] 8]-VIP (SEQ. ID. NO.: 189);
  • [Gln[0249] 8]-VIP (SEQ. ID. NO.: 190);
  • [Ser[0250] 28]-VIP (SEQ. ID. NO.: 191);
  • [Gln[0251] 28]-VIP (SEQ. ID. NO.: 192);
  • [Gln[0252] 12]-VIP (SEQ. ID. NO.: 193);
  • [Gln[0253] 20]-VIP (SEQ. ID. NO.: 194);
  • [Ser[0254] 21]-VIP (SEQ. ID. NO.: 195);
  • [Gln[0255] 21]-VIP (SEQ. ID. NO.: 196);
  • [Met[0256] 13]-VIP (SEQ. ID. NO.: 197);
  • [Ile[0257] 17]-VIP (SEQ. ID. NO.: 198);
  • [Met[0258] 23]-VIP (SEQ. ID. NO.: 199);
  • [Met[0259] 26]-VIP (SEQ. ID. NO.: 200).
  • The preceding list of VIP agonists is by way of example rather than limitation, and other known VIP agonists include permutations of the preceding amino acid sequences and lesser-included deviations from the VIP sequence. Permutations include, for example sequences such as [Thr[0260] 18]-VIP (SEQ. ID. NO.: 201), which is not listed explicitly above but is a lesser-included deviation from the naturally occurring human VIP sequence that is described, for example, in Ac-[Lys12,Nle17,Val26,Ala27,Thr28]-VIP (SEQ. ID. NO.: 21) and Ac-[Lys12,Nle17,Ala16,Thr28]-VIP (SEQ. ID. NO.: 22), as well as a number of other of the above listed VIP analog sequences, for example, SEQ. ID. NO.: 46. Further a permutation of SEQ. ID. NO. 21 and SEQ. ID. NO. 22, is exemplified by Ac-[Lys12,Nle17,Ala26,Ala27,Thr28]-VIP (SEQ. ID. NO.: 202), which substitutes the Ala26 of SEQ. ID. NO.:22 for the Val26 of SEQ. ID. NO.: 21 and is otherwise identical to SEQ. ID. NO.:21.
  • Analogs for use with the instant invention are intended that are essentially equivalent to an explicitly disclosed analog, as specified above. An analog is essentially equivalent to one specified above if it has one or more of the biological activities characteristic of human VIP, has the same number of amino acids as the specified analog and, in comparison with the sequence of the specified analog, has at most five amino acid substitutions, all of which would be considered neutral in the art (i.e., acidic for acidic, basic for basic, uncharged polar for uncharged polar, hydrophobic for hydrophobic, and the like). As is widely known: acidic amino acids are Asp, Glu and gamma-carboxyglutamic acid; basic amino acids are Arg, Lys, His and Orn; hydrophobic amino acids are Ala, Ile, Leu, Met, Nor, Phe, Trp, Tyr, Val, t-butylglycine, norvaline, cyclohexylalanine, t-butylalanine, amino-4-phenylbutyric acid, beta-2-thienylalanine, p-bromophenylalanine, p-chlorophenylalanine, p-iodophenylalanine, p-nitrophenylalanine, 3,5-diiodotyrosine, phenylglycine, and naphthylalanine; uncharged polar amino acids are Asn, Gln, Ser, and Thr. Gly can be substituted for an uncharged polar or a hydrophobic amino acid, but substitutions with Gly are often avoided because helical structures may be destabilized thereby. Substitutions with Pro are generally avoided because of a significant effect on secondary structure of inserting a Pro in place of another amino acid. Substitutions with Cys are also generally avoided because of the reactivity of the sulfhydryl group. [0261]
  • Various synthetic VIP analogs, including many of the above, are explicitly listed in U.S. Pat. Nos. 5,235,907, 5,141,924, 4,734,400 and 4,605,641 to Bolin, and in U.S. Pat. Nos. 4,939,224 and 4,835,252 to Musso et al. [0262]
  • Other suitable VIP agonists include conjugates of VIP and long chain fatty acids or fatty amines, such as CH[0263] 3(CH2)6CO-VIP, CH3(CH2)16CO-VIP, CH3(CH2)16CO-VIP7-28, CH3(CH2)16CO-VIP16-28, VIP-CONH—CH2CH3, VIP-CONH—(CH2)3CH3, and VIP-CONH-(CH2)7CH3, the synthesis of which is described in U.S. Pat. No. 5,147,855 to Gozes et al.
  • Still other suitable VIP agonists are nitrosylated VIP analogs having the structure VIP-Gly-Cys-NO (SEQ. ID NO.: 203), and the related analogs VIP-Gly-Cys-NH[0264] 2 (SEQ. ID NO.: 204) and VIP-Gly-Cys (SEQ. ID NO.: 205), preparation of which is described in U.S. Pat. No. 5,612,314 to Stamler et al.
  • VIP analogs known in the art that are useful for practicing the present invention include those compounds listed above and others that exhibit agonistic VIP activity, preferably strong agonistic activity. Also preferred are those analogs that exhibit agonistic activity with a relatively long biological activity, e.g. a relatively long pharmacologic half-life. Methods for determining the agonistic VIP activity and half-life of a given VIP analog are known to those ordinarily skilled in the art. One attribute of a VIP analog that makes it useful for practicing the invention is a resistance to hydrolysis, a property of synthetic VIP analogs that are disclosed in U.S. Pat. No. 4,939,224 to Musso et al. for bronchodilation. [0265]
  • As the practice of the instant invention will often if not typically involve topical delivery of the vasoactive VIP agonists to the female sex organs, absorption of the VIP analog through the epithelium covering the organ or organs to which it is applied is required for the desired pharmacologic effects. The ordinarily skilled artisan in the therapeutic pharmaceutical art will be able to ascertain whether the absorption of a particular VIP analog is sufficient for the desired effects. VIP analogs are expected to be capable of crossing such epithelial barriers, as the peptide is small relative to proteins. [0266]
  • The ability of VIP peptides to cross such epithelial barriers has been demonstrated in the context of administering VIP by inhalation for bronchodilation. Although administration by inhalation has been shown to be more tissue specific and to have fewer side-effects than intravenous administration but appears to be less effective than intravenous administration (Altiere et al. (1983) [0267] Pharmacologist 25:123; Bundgaard et al. (1983) Eur. J. Respir. Dis. 64(Suppl. 128):427-429; Altiere et al. (1984) Chest 86:153-154. This observed lower efficacy of VIP in bronchodilation when administered by inhalation, compared with administration intravenously, is thought to be caused by one or a combination of: (1) rapid degradation of VIP by compounds, including proteolytic enzymes, present in the respiratory tract both in the bronchial airways and the passageways leading thereto (Barrowcliffe et al. (1986) Thorax 41:88-93); or (2) limited absorption of VIP through nasal and pulmonary mucosa, due in part to the size of VIP (about 3300 Daltons)(Effros and Mason (1982) Am. Rev. Resp. Dis. 127:S59-S65; Altiere et al. (1984) supra).
  • In the context of the present invention, the ability of various VIP analogs that exhibit VIP agonist activity to cross the pertinent epithelial barrier as a naked peptide is expected. Further, those of skill in the art will appreciate that the ability of VIP agonists to cross the epithelial barrier of the female genitalia for use with the instant invention may be enhanced by known techniques, such as packaging in liposomes or the like. [0268]
  • The above representative VIP analogs may be readily synthesized by known conventional techniques for forming a peptide linkage between amino acids. Such conventional procedures include, for example, all solution phase techniques permitting a condensation between the free alpha amino group of an amino acid or residue thereof having its carboxyl group or other reactive groups protected and the free primary carboxyl group of another amino acid or residue thereof having its amino group or other reactive groups protected. [0269]
  • The process for synthesizing the representative compounds may be carried out by a procedure whereby each amino acid in the desired sequence is added one at a time in succession to another amino acid or residue thereof or by a procedure whereby peptide fragments with the desired amino acid sequence are first synthesized conventionally and then condensed to provide the desired peptide. [0270]
  • Such conventional procedures for synthesizing the active agents of the present invention include for example any solid phase peptide synthesis method. In such a method the synthesis of the active agents can be carried out by sequentially incorporating the desired amino acid residues one at a time into the growing peptide chain according to the general principles of solid phase methods (Merrifield (1963) [0271] J. Amer. Chem. Soc. 85:2149-2154; Barany et al, The Peptides, Analysis, Synthesis and Biology, Vol. 2, 1-284 Gross, E. and Meienhofer, J., Eds. (Academic Press 1980)).
  • The chemical syntheses of peptides is widely appreciated to require the protection of reactive side chain groups of the various amino acid moieties, in addition to α-amino or α-carboxyl group of the reacted amino acids, with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the protecting group is ultimately removed. Groups requiring such protection include: α-amino, side chain-amino, carboxyl, hydroxyl, side chain amide, guanidino and imidazole. Methods for protecting both reactive side chain groups and α-amino or α-carboxyl groups are known in the art and enumerated in U.S. Pat. Nos. 5,235,907, 5,141,924, 4,734,400 and 4,605,641 to Bolin. Although the synthetic organic methods described in the preceding publications may be employed to synthesize VIP analogs described above, many may also be expressed in eukaryotic or prokaryotic cells by use of the appropriate expression vector. [0272]
  • Additional pharmacologically active agents may be co-administered along with the primary active agent, i.e., with the VIP or VIP agonist. Such additional active agents are also referred to herein as “secondary” active agents. Preferred secondary agents are vasoactive agents, particularly vasodilators, selected from the group consisting of vasoactive prostaglandins, endothelin-derived relaxation factors, smooth muscle relaxants, leukotriene inhibitors, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs, active metabolites, and inclusion complexes thereof, and combinations of any of the foregoing. Other suitable secondary agents include rho kinase inhibitors, melanocortin peptides, endothelin antagonists, growth factors and other peptidyl drugs; selective androgen receptor modulators (SARMs), neuropeptides, amino acids, serotonin agonists, serotonin antagonists, calcium channel blockers, potassium channel openers, potassium channel blockers, dopamine agonists, dopamine antagonists, non-androgenic steroid hormones, and combinations thereof. [0273]
  • Particularly preferred vasoactive agents are vasoactive prostaglandins selected from the group consisting of naturally occurring prostaglandins, semisynthetic prostaglandins, synthetic prostaglandins, and pharmaceutically acceptable, pharmacologically active salts, esters, amides, inclusion complexes prodrugs, metabolites, and analogs thereof. Racemic, optically enriched or purified stereoisomers of any of these compounds are also included. A suitable unit dose of a prostaglandin herein is in the range of approximately 1 to 5000 μg, preferably in the range of approximately 20 to 2000 μg. Preferred prostaglandins include, but are not limited to, the naturally occurring prostaglandins prostaglandin E[0274] 0 (PGE0, also referred to 13,14-dihydro-PGE1, hereinafter, the abbreviation “PG” is used for “prostaglandin”), PGE1, 19-hydroxy-PGE1, PGE2, 19-hydroxy-PGE2,PGA1, 19-hydroxy-PGA1, PGA2, 19-hydroxy-PGA2, PGB1, 19-hydroxy-PGB1, PGB2, 19-hydroxy-PGB2, PGB3, PGD2, PGF1α, PGF2α,(dinoprost), PGE3, PGF3α, PGI2 (prostacyclin), and combinations thereof. PGE0, PGE1, PGE2, and the hydrolyzable lower alkyl esters thereof (e.g., the methyl, ethyl and isopropyl esters) are, however, particularly preferred. Other suitable prostaglandins are exemplified, without limitation, by arboprostil, carbaprostacyclin, carboprost tromethamine, dinoprost tromethamine, dinoprostone, enprostil, iloprost, lipoprost, gemeprost, metenoprost, sulprostone, tiaprost, viprostil (CL 115,347), viprostil methyl ester, 16,16-dimethyl-Δ2-PGE1, methyl ester, 15-deoxy-16-hydroxy-16-methyl-PGE1, methyl ester (misoprostol), 16,16-dimethyl-PGE1, 11-deoxy-15-methyl-PGE1, 16-methyl-18,18,19,19-tetrahydrocarbacyclin, 16(RS)-15-deoxy-16-hydroxy-16-methyl-PGE1, methyl ester, (+)-4,5-didehydro-16-phenoxy-α-tetranor-PGE2 methyl ester, 11-deoxy-11α, 16,16-trimethyl-PGE2, (+)-11α, 16α, 16β-dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl-trans-prostene, 9-chloro-16,16-dimethyl-PGE2, 16,16-dimethyl-PGE2, 15(S)-15-methyl-PGE2, 9-deoxy-9-methylene-16,16-dimethyl-PGE2, potassium salt, 19(R)-hydroxy-PGE2, and 11-deoxy-16,16-dimethyl-PGE2.
  • Additional vasoactive agents useful as secondary active agents herein include endothelin-derived relaxation factors (“EDRFs”) such as nitric oxide releasing agents, e.g., sodium nitroprusside and diazenium diolates, or “NONOates.” NONOates include, but are not limited to, (Z)-1-{N-methyl-N-[6-(N-methyl-ammoniohexyl)amino]}diazen-1-ium-1,2-diolate (“MAHMA/NO”), (Z)-1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]-diazen-1-ium-1,2-diolate (“PAPA/NO”), (Z)-1- {N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]amino}diazen-1-ium-1,2-diolate (spermine NONOate or “SPER/NO”) and sodium (Z)-1-(N,N-diethylamino)-diazen-1-ium-1,2-diolate (diethylamine NONOate or “DEA/NO”) and derivatives thereof). Still other vasoactive agents include vasoactive intestinal polypeptide analogs and derivatives thereof (particularly derivatives in the form of hydrolyzable lower alkyl esters), smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, β2-adrenergic agonists, angiotensin-converting enzyme (“ACE”) inhibitors, angiotensin II receptor antagonists, and phosphodiesterase inhibitors. [0275]
  • Still other suitable vasoactive agents include, but are not limited to: nitrates and like compounds such as nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, molsidomine, linsidomine chlorhydrate (“SIN-1”), S-nitroso-N-acetyl-d,1-penicillamine (“SNAP”) and S-nitroso-N-glutathione (“SNO-GLU”); long and short acting α-blockers such as phenoxybenzamine, dibenamine, doxazosin, terazosin, phentolamine, tolazoline, prazosin, trimazosin, alfuzosin, tamsulosin and indoramin; ergot alkaloids such as ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride and terguride; antihypertensive agents such as diazoxide, hydralazine and minoxidil; nimodepine; pinacidil; cyclandelate; dipyridamole; isoxsuprine; chlorpromazine; haloperidol; yohimbine; and trazodone. [0276]
  • Other secondary active agents herein are inhibitors of rho kinase, an enzyme belonging to the rhoA/rho associated kinase pathway, which regulates the state of phosphorylation of myosin phosphatase, in turn leading to the control of smooth muscle contraction. One example of a suitable rho kinase inhibitor has the structural formula [0277]
    Figure US20020099003A1-20020725-C00002
  • and is identified as Y-27632. Other suitable rho kinase inhibitors are disclosed, for example, in U.S. Pat. No. 6,218,410. [0278]
  • Additional secondary agents useful herein are peptide analogs of α-melanocyte-stimulating hormone (α-MSH), also referred to as “melanocortin peptides.” Such peptides include the sequence His-Phe-Arg-Trp, His-D-Phe-Arg-Trp, or are homologs thereof, and are preferably cyclic. A preferred melanocortin peptide is Ac-Nle-cyclo-(-Asp-His-D-Phe-Arg-Trp-Lys)—OH. See U.S. Pat. No. 6,051,555 to Hadley and International Patent Publication No. WO 01/00224 to Blood et al., assigned to Palatin Technologies, Inc. The aforementioned amino acid residues have their conventional meaning as given in Chapter 2422 of the [0279] Manual of Patent Examining Procedure (2000). Thus, “Arg” is arginine, “Nle” is norleucine, “His” is histamine, “Phe” is phenylalanine, “D-Phe” is D-phenylalanine, “Trp” is tryptophan, and “Ac” refers to an acetyl moiety, i.e., an acetyl moiety present in a peptide or amino acid sequence that is acetylated.
  • Suitable endothelin antagonists include antagonists of any or all of the three isoforms of endothelin, i.e., ET-1, ET-2, and ET-3, and are exemplified by: phenoxyphenylacetic acids and derivatives thereof, such as N-(4-isopropylbenzene-sulbonyl)-α-(4-carboxy-2-n-propylphenoxy)-3,4-methylenedioxyphenyl acetamide dipotassium salt, 2-[(2,6-dipropyl-4-hydroxymethyl)-phenoxy]-2-(4-phenoxyphenyl)-acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(4-phenylphenyl)acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3-carboxyphenyl)-acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-ethylenedioxyphenyl)acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4,5-trimethoxyphenyl)acetic acid, 2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-methylenedioxyphenyl)acetic acid, N-(4-dimethylaminobenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl) acetamide, N-(2-methylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide, N-(2-methoxycarbonyl-benzenesulfonyl)-2-(4-methoxy-carbonyl-2-propylphenoxy)-2-(3,4-methylenedioxy-phenyl)acetamide, N-(2-chlorobenzene-sulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide, and others, as described in U.S. Pat. No. 5,565,485; and certain isooxazoles, oxazoles, thiazoles, isothiazoles and imidazoles, as described, for example, in U.S. Pat. No. 6,136,828. Numerous other endothelin antagonists may be used as secondary agents herein, and will be known to those of ordinary skill in the art and/or are described in the pertinent patents, literature and texts. [0280]
  • Peptidyl drugs include the peptidyl hormones activin, amylin, angiotensin, atrial natriuretic peptide (ANP), calcitonin, calcitonin gene-related peptide, calcitonin N-terminal flanking peptide, ciliary neurotrophic factor (CNTF), corticotropin (adrenocorticotropin hormone, ACTH), corticotropin-releasing factor (CRF or CRH), epidermal growth factor (EGF), follicle-stimulating hormone (FSH), gastrin, gastrin inhibitory peptide (GIP), gastrin-releasing peptide, gonadotropin-releasing factor (GnRF or GNRH), growth hormone releasing factor (GRF, GRH), human chorionic gonadotropin (hCH), inhibin A, inhibin B, insulin, luteinizing hormone (LH), luteinizing hormone-releasing hormone (LHRH), α-melanocyte-stimulating hormone, β-melanocyte-stimulating hormone, γ-melanocyte-stimulating hormone, melatonin, motilin, oxytocin (pitocin), pancreatic polypeptide, parathyroid hormone (PTH), placental lactogen, prolactin (PRL), prolactin-release inhibiting factor (PIF), prolactin-releasing factor (PRF), secretin, somatotropin (growth hormone, GH), somatostatin (SIF, growth hormone-release inhibiting factor, GIF), thyrotropin (thyroid-stimulating hormone, TSH), thyrotropin-releasing factor (TRH or TRF), thyroxine, and vasopressin. Other peptidyl drugs are the cytokines, e.g., colony stimulating factor 4, heparin binding neurotrophic factor (HBNF), interferon-α, interferon α-2a, interferon α-2b, interferon α-n3, interferon-β, etc., interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, etc., tumor necrosis factor, tumor necrosis factor-α, granuloycte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor, midkine (MD), and thymopoietin. [0281]
  • Selective androgen receptor modulators (SARMs) include LGD2226 and/or LGD1331, both available from Ligand Pharmaceuticals (San Diego, Calif.). See Negro-Villar et al. (1999) [0282] J. Clin. Endocrinol. & Metabol. 84(10):3459-62.
  • Suitable neuropeptides include bradykinin, kallidin, des- Arg[0283] 9-bradykinin, des-Arg10-kallidin, des-Arg9-[Leu8]-bradykinin, [D-Phe7]-bradykinin, HOE 140, neuropeptide Y, calcitonin gene-related peptide (cGRP), enkaphalins and related opioid peptides such as Met5-enkaphalin, Leu5-enkephalin, α-, β- and γ-endorphin, α- and β- neo-endorphin, and dynorphin, as well as the neurotransmitters GABA (γ-aminobutyric acid), glycine, glutamate, acetylcholine, dopamine, epinephrine, 5-hydroxytryptamine, substance P, serotonin, and catecholamines.
  • One or more amino acids may be included in the present formulations. As used herein, the term “amino acid” includes the conventional amino acids, e.g., phenylalanine, leucine, isoleucine, methionine, valine, serine, proline, threonine, alanine, tyrosine, histidine, glutamine, asparagine, lysine, aspartic acid, glutamic acid, cysteine, tryptophan, arginine, and glycine, with arginine being particularly preferred. In addition, the term “amino acid” will also include amino acid derivatives, e.g., 1-naphthylalanine, 2-naphthylalanine, 3-pyridylalanine, 4-hydroxyproline, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and nor-leucine, in addition to stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids. Combinations of any of the foregoing are contemplated as well. Preferred amino acids are the neuroactive amino acids γ-aminobutyric acid (GABA), glycine, β-alanine, taurine, and glutamate. [0284]
  • Suitable serotonin agonists include, but are not limited to 2-methyl serotonin, buspirone, ipsaperone, tiaspirone, gepirone, ergot alkaloids, 8-hydroxy-(2-N,N-dipropyl-amino)-tetraline, 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane, cisapride, sumatriptan, m-chlorophenylpiperazine, trazodone, zacopride, mezacopride, and combinations thereof. Suitable serotonin antagonists include, for example, ondansetron, granisetron, metoclopramide, tropisetron, dolasetron, palonosetron, trimethobenzamide, methysergide, risperidone, ketanserin, ritanserin, clozapine, amitriptyline, MDL 100,907 (R(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine-methanol) (Marion Merrell Dow), azatadine, cyproheptadine, fenclonine, chlorpromazine, mianserin and combinations thereof. [0285]
  • Representative ergot alkaloids include ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile, dihydroergotamine, disulergine, ergonovine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride and terguride. [0286]
  • Calcium channel blockers that are suitable for use according to the present invention include, without limitation, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, bepridil, diltiazem, verapamil, and combinations thereof. [0287]
  • Potassium channel openers include, but are not limited to, pinacidil, diazoxide, cromakalim, nicorandil, minoxidil, (N-cyano-N′-(1,1-dimethylpropyl)-N″-3-pyridyl-guanidine (P-1075), and N-cyano-N′-(2-nitroxyethyl)-3-pridinecarboximidamide monomethanesulfonate (KRN 2391). [0288]
  • Potassium channel blockers include tedisamil, agitoxin-2, apamin, BDS-I, BDS-II, charybdotoxin, α-dendrotoxin, β-dendrotoxin, γ-dendrotoxin, δ-dendrotoxin, dendrotoxin-I, dendrotoxin-K, E-4031, iberiotoxin, kaliotoxin, MCD-peptide, margatoxin, noxiustoxin, paxilline, penitrem A, stichodactyla, tertiapin, tityustoxin K alpha, verruculogen, and combinations thereof. Although all of the active agents are available commercially, most of the listed potassium channel blockers are available from Alomone Labs (Jerusalem, Israel). [0289]
  • Suitable dopamine agonists include, for example, levodopa, bromocriptine, pergolide, apomorphine, piribedil, pramipexole, ropinirole, and combinations thereof. Dopamine antagonists include, without limitation, spiroperidol, benperidol, trifluperidol, pimozide, fluphenazine, droperidol, haloperidol, thiothixene, trifluperazine, moperone, prochlorperazine, molindone, thioridazine, clozapine, chlorpromazine, promazine, sulpiride, clebopride, chlorpromazine, spiperone, flupenthixol, and combinations thereof. [0290]
  • Non-androgenic steroids that may be administered as secondary active agents include progestins and estrogens. Suitable estrogens include synthetic and natural estrogens such as: estradiol (i.e., 1,3,5-estratriene-3,17β-diol, or “17β-estradiol”) and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17α-estradiol; ethinylestradiol (i.e., 17α-ethinylestradiol) and esters and ethers thereof, including ethinylestradiol 3-acetate and ethinylestradiol 3-benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate, and piperazine estrone sulfate; quinestrol; mestranol; and conjugated equine estrogens. Suitable progestins include acetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17α-ethinyltestosterone), ethynodiol diacetate, flurogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol acetate, norethindrone, norethindrone acetate, norethisterone, norethisterone acetate, norethynodrel, norgestimate, norgestrel, norgestrienone, normethisterone, and progesterone. It is generally desirable to co-administer a progestin along with an estrogen so that the estrogen is not “unopposed.” As is well known in the art, estrogen-based therapies are known to increase the risk of endometrial hyperplasia and cancer, as well as the risk of breast cancer, in treated individuals. Co-administration of estrogenic agents with a progestin has been found to decrease the aforementioned risks. [0291]
  • The primary vasoactive agent—i.e., VIP or an agonist thereof—and the additional active agent or agents may be incorporated into a single formulation, or they may be administered separately, either simultaneously or sequentially. In a preferred embodiment, an androgenic agent is administered prior to administration of VIP or a VIP agonist, i.e., the androgenic agent is administered as a pretreatment. In a particularly preferred embodiment, such a method involves administration of an androgenic agent, e.g., via oral or topical (preferably vulvar and/or vaginal) administration, followed by topical (again, preferably vulvar and/or vaginal) administration of VIP or a VIP agonist. [0292]
  • The formulations herein are administered by topical application to the vulvar region and/or by vaginal drug administration. These pharmaceutical formulations will typically contain one or more pharmaceutically acceptable carriers suited to the particular type of formulation, i.e., gel, ointment, suppository, or the like. The vehicles are comprised of materials of naturally occurring or synthetic origin that do not adversely affect the active agent or other components of the formulation. Suitable carriers for use herein include water, silicone, waxes, petroleum jelly, polyethylene glycol, propylene glycol, liposomes, sugars such as mannitol and lactose, and a variety of other materials, again depending, on the specific type of formulation used. As described in Section IV, infra, dosage forms used for administration to the vulvar region and/or vagina may be used to deliver drug on an as-needed, on-demand basis, and/or throughout an extended, sustained release profile. [0293]
  • The formulations may also include a chemical compound to enhance permeation of the active agent through the mucosal tissue, i.e., a “permeation enhancer.” Suitable permeation enhancers include those generally useful in conjunction with topical, transdermal or transmucosal drug delivery. Examples of suitable permeation enhancers include the following: sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C[0294] 10MSO); ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No. 4,783,450); the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclaza-cycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, Calif.; see U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616 and 4,557,934); alcohols such as ethanol, propanol, octanol, decanol, benzyl alcohol, and the like; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate; polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No. 4,568,343); amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes; alkanones; and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid. Mixtures of two or more enhancers may also be used.
  • In some cases, the formulations may include an enzyme inhibitor, i.e., a compound effective to inhibit enzymes present in the vagina or vulvar area that could degrade or metabolize the active agent. That is, inhibitors of enzymes that decrease or eliminate the activity of the active agent may be included in the formulation so as to effectively inhibit the action of those enzymes. Such compounds include, for example, fatty acids, fatty acid esters, and NAD inhibitors. [0295]
  • The formulations may be in the form of an ointment, cream, emulsion, lotion, gel, solid, solution, suspension, foam or liposomal formulation. Alternatively, the formulations may be contained within a vaginal ring (e.g., as disclosed in U.S. Pat. No. 5,188,835 to Lindskog et al., assigned to Kabi Pharmacia AB), or within a tampon, suppository, sponge, pillow, puff, or osmotic pump system; these platforms are useful solely for vaginal delivery. [0296]
  • Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. The specific ointment base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As explained in [0297] Remington: The Science and Practice of Pharmacy, supra, at pages 1034-1038, ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy for further information.
  • Lotions are preparations that may be applied without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are usually suspensions of solids, and preferably, for the present purpose, comprise a liquid oily emulsion of the oil-in-water type. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethylcellulose, or the like. [0298]
  • Pharmaceutical emulsion formulations are generally formed from a dispersed phase (e.g., a pharmacologically active agent), a dispersion medium and an emulsifying agent. If desired, emulsion stabilizers can be included in the formulation as well. A number of pharmaceutically useful emulsions are known in the art, including oil-in-water (o/w) formulations, water-in-oil (w/o) formulations and multiple emulsions such as w/o/w or o/w/o formulations. Emulsifying agents suitable for use in such formulations include, but are not limited to, TWEEN 60®, Span 80®, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. [0299]
  • Pharmaceutical creams are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase, also sometimes called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. [0300]
  • The above pharmaceutical formulations are formed by dispersing the finely divided or dissolved active agent uniformly throughout the vehicle or base using conventional techniques, typically by a levigating the agent with a small quantity of the base to form a concentrate, which is then diluted geometrically with further base. Alternatively, a mechanical mixer may be used. Creams, lotions and emulsions are formed by way of a two-phase heat system, wherein oil-phase ingredients are combined under heat to provide a liquified, uniform system. The aqueous-phase ingredients are separately combined using heat. The oil and aqueous phases are then added together with constant agitation and allowed to cool. At this point, concentrated agents may be added as a slurry. Volatile or aromatic materials can be added after the emulsion has sufficiently cooled. Preparation of such pharmaceutical formulations is within the general skill of the art. [0301]
  • The active agent can also be incorporated into a gel formulation using known techniques. Two-phase gel systems generally comprise a suspension or network of small, discrete particles interpenetrated by a liquid to provide a dispersed phase and a liquid phase. Single-phase gel systems are formed by distributing organic macromolecules uniformly throughout a liquid such that there are no apparent boundaries between the dispersed and liquid phases. Suitable gelling agents for use herein include synthetic macromolecules (e.g., Carbomers®, polyvinyl alcohols and polyoxyethylene-polyoxypropylene copolymers), gums such as tragacanth, as well as sodium alginate, gelatin, methylcellulose, sodium carboxymethylcellulose, methylhydroxyethyl cellulose and hydroxyethyl cellulose. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof. [0302]
  • Liposomes are microscopic vesicles having a lipid wall comprising a lipid bilayer, and can be used as drug delivery systems herein as well. Generally, liposome formulations are preferred for poorly soluble or insoluble pharmaceutical agents. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (“DOTMA”) liposomes are available under the tradename Lipofectin® (GIBCO BRL, Grand Island, N.Y.). Similarly, anionic and neutral liposomes are readily available as well, e.g., from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (“DOPC”), dioleoylphosphatidyl glycerol (“DOPG”), dioleoylphoshatidyl ethanolamine (“DOPE”), among others. These materials can also be mixed with DOTMA in appropriate ratios. Methods for making liposomes using these materials are well known in the art. [0303]
  • Vaginal suppositories are typically manufactured with polyethylene glycol (PEG), polyethylene oxide and/or other low melting point or water-soluble polymers including fatty acid esters. Suppositories may also be applied to the vulvar region, in which case these dosage forms, which are solid at ambient temperature, rapidly melts when placed on the clitoris and within the vulvar region. [0304]
  • Typically, compositions and dosage forms for vulvar and/or vaginal administration will contain the active agent in a concentration such that an effective amount of the agent is delivered with a single application. For example, the composition or dosage form will generally contain sufficient active agent such that an effective amount of the agent is delivered by application of about 0.1 g to 1.0 g. Thus, for delivering about 1.0 μg to about 100 mg, preferably about 0.05 mg to about 50 mg, most preferably about 1.0 mg to about 25 mg, of the composition or dosage form will contain the active agent at a concentration in the range of about 1.0 μg/g to about 1.0 g/g, preferably 50 μg/g to about 500 mg/g, most preferably about 1.0 mg/g to about 250 mg/g. [0305]
  • Delivery of an “as-needed” or “on-demand” dose with topical formulations intended for application to the vulvar region, and/or with vaginal suppositories, is effected by using the appropriate carrier and, when necessary, excipients, for the particular active agent. For example, the active agent's affinity to the carrier must be lower than its affinity to the treated body surface. Optimally, the agent will have a relatively high affinity for the mucosal surface to which it is applied, and a relatively low affinity for the particular carrier. As the affinity of the agent for the body surface remains constant (assuming the agent does not change, e.g., hydrolyze, etc., upon contact with the body surface), a suitable carrier for use in the formulations described herein can be determined by routinely testing a series of different carriers containing the active agent and selecting those carriers that provide the greatest flux of the active agent to the intended tissue, e.g., clitoral tissue. Additionally, one or more permeation enhancers and/or detergents may also be present in the formulation to ensure a rate of delivery sufficient for on-demand administration. A combination of these approaches as well as other approaches may be used to effect delivery of an on-demand dose. [0306]
  • Once the initial, on-demand dose is delivered, the drug delivery system, if present, and/or any remaining formulation may be removed or may remain in place, depending on the preferences of the individual. Alternatively, the formulation and optional drug delivery system may be designed to provide both initial “on-demand” release of the active agent, i.e., as a single, bolus dose, as well as sustained release thereafter, e.g., pulsatile, continuous or cyclical drug release. Such systems can include, for example, osmotic release systems that are capable of delivering an initial, on-demand release of the active agent in addition to variable amounts of the agent in a pulsatile manner thereafter. [0307]
  • Other drug delivery platforms capable of providing an initial release of drug followed by a pulsatile, continuous or cyclical agent release profile include those formed from bioerodible polymers, wherein the active agent is dispersed within a polymer matrix that is surrounded by an immediate release coating of the agent. The immediate release coating ensures effective on-demand administration. The polymers forming the matrix are selected such that they bioerode in the presence of moisture, and provide for sustained agent release at readily predictable rates. [0308]
  • More particularly, release of the active agent can be controlled by dissolution (bioerosion) of a polymer using either encapsulated dissolution control or matrix dissolution control. In encapsulated dissolution control, the on-demand dose of the active agent is located within an outer polymeric or wax membrane that dissolves to provide an initial release of the agent. When the encapsulating membrane comprising an initial release of the agent has dissolved, a core containing additional active agent is then available for release and adsorption across the epithelial or mucosal surfaces of the vagina or vulvar area. Bioerodible coating materials may be selected from a variety of natural and synthetic polymers, depending on the agent to be coated and the desired release characteristics. Exemplary coating materials include gelatins, carnauba wax, shellacs, ethylcellulose, cellulose acetate phthalate or cellulose acetate butyrate. Following the immediate release of the agent, a uniform sustained release of the agent can be attained by compressing a population of particles of the agent with varying membrane thickness (e.g., varying erosion times) into a tablet form for a single administration. [0309]
  • In matrix dissolution control, the active agent is dissolved or dispersed within a matrix of, for example, an erodible wax. The agent is released for adsorption across the epithelial or mucosal surfaces of the vagina or vulvar area as the matrix bioerodes. The rate of agent availability is generally controlled by the rate of penetration of the dissolution media (i.e., vaginal fluids) into the matrix, wherein the rate of penetration is dependent on the porosity of the matrix material. Bioerodible matrix dissolution delivery systems can be prepared by compressing the active agent with a slowly soluble polymer carrier into a tablet or suppository form. There are several methods of preparing drug/wax particles including congealing and aqueous dispersion techniques. In congealing methods, the active agent is combined with a wax material and either spray-congealed, or congealed and then screened. For an aqueous dispersion, the active agent/wax combination is sprayed or placed in water and the resulting particles collected. Matrix dosage formulations can be formed by compaction or compression of a mixture of active agent, polymer and excipients. Of course, the active agent will also be located in an external coating of the matrix formulation to provide for immediate release of the active agent necessary for on-demand administration. [0310]
  • In an alternative embodiment, the pharmaceutical formulation is administered in the form of biodegradable adhesive film or sheet that adheres to the vulvar area. Such drug delivery systems are generally composed of a biodegradable adhesive polymer based on a polyurethane, a poly(lactic acid), a poly(glycolic acid), a poly(ortho ester), a polyanhydride, a polyphosphazene, or a mixture or copolymer thereof. Preferred biodegradable adhesive polymers include polyurethanes and block copolyurethanes containing peptide linkages, simple mixtures of polyurethanes and polylactides, and copolymers of acrylates and mono- or disaccharide residues. [0311]
  • Preferred dosage forms contain a unit dose of active agent, i.e., a single therapeutically effective dose. For creams, ointments, etc., a “unit dose” requires an active agent concentration that provides a unit dose in a specified quantity of the formulation to be applied, as explained supra. The unit dose of any particular active agent will depend, of course, on the active agent, the needs of the patient, and on the mode of administration. Those of ordinary skill in the art of pharmaceutical formulation can readily deduce suitable unit doses for VIP and various VIP agonists, as well as suitable unit doses for other types of active agents that may be incorporated into a dosage form of the invention. [0312]
  • Drug administration is preferably, although not necessarily, on an as-needed basis, in which case chronic drug administration is not involved. With an immediate release dosage form, i.e., a composition or dosage form that is not “controlled release” as defined hereinabove, as-needed administration may involve drug administration immediately prior to sexual activity, but will generally be in the range of about 0.25 to 72 hours, preferably about 0.5 to 48 hours, more preferably about 1 to 24 hours, most preferably about 1 to 12 hours, and optimally about 1 to 4 hours prior to anticipated sexual activity. As will be appreciated by those in the fields of pharmacology and drug delivery, the upper end of the aforementioned ranges will depend on the pharmacokinetics of the particular active agent administered. [0313]
  • With a sustained release dosage form, a single “as-needed” dose can provide therapeutic efficacy over an extended time period in the range of about 4 to 72 hours, typically in the range of about 4 to 48 hours, more typically in the range of about 4 to 24 hours, depending on the formulation. The release period may be varied by the selection and relative quantity of particular sustained release polymers, as discussed supra. [0314]
  • As-needed administration as described herein has several advantages over chronic pharmacologic intervention. First, chronic administration of some agents, in particular steroids, can result in serious medical complications and alter the balance of naturally occurring steroids in the body. Second, patient compliance can be problematic with a regimented dosing scheme. Furthermore, as-needed administration is convenient and doses are taken only in anticipation of sexual activity. Thus, needless expenditure on wasted dosages is avoided, thereby decreasing the treatment's overall expense. [0315]
  • The patient treated may be a woman suffering from some type of sexual dysfunction or disorder, or may possess “normal” sexual desire and/or “normal” sexual responsiveness as those terms are understood defined by clinicians or other experts. For these “normal” women, the present invention offers heightened sexual desire and responsiveness relative to her typical sexual experience. Often, however, the female patient seeking enhanced sexual desire and responsiveness suffers a sexual dysfunction such as a condition, disease or disorder that affects one of the four stages of the female sexual response: excitement, plateau, orgasm, or resolution. More specifically, the patient may suffer from any one or more of the following: [0316]
  • a decrease in or absence of female sexual responsiveness or female sexual desire; [0317]
  • a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity; [0318]
  • a decrease in the physiological response to sexual stimulation such as, but not limited to, slowed, decreased or absent erectile response of the female erectile tissues; slowed, decrease or absent lubrication of the vagina; slowed decreased or absent ability to reach orgasm, and decreased intensity of or pleasure in orgasms; [0319]
  • frigidity; [0320]
  • sexual aversion; [0321]
  • a condition, disease or disorder that may result in decreased sexual desire and responsiveness including, but not limited to, the menopausal or post-menopausal state, radiotherapy of the pelvis, multiple sclerosis, atherosclerosis, pelvic trauma or surgery, peripheral neuropathies, autonomic neuropathies, diabetes mellitus, and disorders of the innervation of any of the sexual organs; [0322]
  • substance-induced decreases in sexual desire and responsiveness including, but not limited to, decreases related to the administration of pharmacologic agents such as, but not limited to, anti-depressants, neuroleptics, anti-hypertensives, opiates, alcohol, and any other agent found to decrease or eliminate any part of the sexual response cycle; and [0323]
  • primary and secondary anorgasmia. [0324]
  • In addition to enhancing female sexual desire and responsiveness, the method, compositions and dosage forms of the invention are useful in improving the tissue health of the female genitalia and preventing vaginal atrophy, preventing pain during intercourse as a result of dyspareunia, and alleviating vaginal itching and dryness associated with dyspareunia and other conditions. [0325]
  • In another embodiment, a packaged kit is provided that contains the pharmaceutical formulation to be administered, i.e., a pharmaceutical formulation containing VIP or a VIP agonist for enhancing female sexual desire and responsiveness, a container (e.g., a vial, a bottle, a pouch, an envelope, a can, a tube, an atomizer, an aerosol can, etc.), preferably sealed, for housing the formulation during storage and prior to use, and instructions for carrying out drug administration in a manner effective to enhance sexual desire and responsiveness. The instructions will typically be written instructions on a package insert, a label, and/or on other components of the kit. [0326]
  • Depending on the type of formulation and the intended mode of administration, the kit may also include a device for administering the formulation (e.g., a transdermal delivery device). The administration device may be a dropper, a swab, a stick, or the nozzle or outlet of an atomizer or aerosol can. The formulation may be any suitable formulation as described herein. For example, the formulation may be an oral dosage form containing a unit dosage of the active agent, or a gel or ointment contained within a tube. The kit may contain multiple formulations of different dosages of the same agent. The kit may also contain multiple formulations of different active agents. [0327]
  • The present kits will also typically include means for packaging the individual kit components, i.e., the pharmaceutical dosage forms, the administration device (if included), and the written instructions for use. Such packaging means may take the form of a cardboard or paper box, a plastic or foil pouch, etc. [0328]
  • It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples that follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains. [0329]
  • All patents, patent applications, patent publications and non-patent literature references mentioned herein are incorporated by reference in their entireties. [0330]
    • EXAMPLE 1
  • A cream formulation is prepared for the topical administration of VIP. The cream includes the following components: [0331]
    VIP 750 mg
    Beeswax 2.7 g
    Carbopol ® 934 q.s. 100.0 g
  • Mixing is conducted with tile and spatula until a homogeneous cream mixture is obtained having the prostaglandin uniformly dispersed throughout the composition. [0332]
    • EXAMPLE 2
  • The procedure of Example 1 is repeated except that the following components are used: [0333]
    Stearyl-VIP 500 mg
    Polyethylene glycol 400 37.5 g
    1,2,6-hexanetriol 20.0 g
    Polyethylene glycol 4000 q.s. 100.0 g
  • Stearyl-VIP is prepared as described in U.S. Pat. No. 5,147,855 to Gozes et al. A homogenous cream mixture is obtained. [0334]
    • EXAMPLE 3
  • The procedure of Example 1 is repeated except that the following components are used: [0335]
    Stearyl VIP7-28 750 mg
    Polyethylene glycol 400 37.0 g
    Polyethylene glycol 400 monostearate 26.0 g
    Polyethylene glycol 4000 q.s. 100.0 g
  • Stearyl-VIP is prepared as described in U.S. Pat. No. 5,147,855 to Gozes et al. A homogenous cream mixture is obtained. [0336]
    • EXAMPLE 4
  • The procedure of Example 1 is repeated except that the following components are used: [0337]
    VIP-Gly-Cys-NH2 (SEQ. ID NO.: 204) 750 mg
    Polyethylene glycol 400 47.5 g
    Cetyl Alcohol 5.0 g
    Polyethylene glycol 4000 q.s. 100.0 g
  • VIP-Gly-Cys-NH[0338] 2 (SEQ. ID NO.: 204) is prepared as described in U.S. Pat. No. 5,612,314 to Stamler et al. A homogenous cream mixture is obtained.
    • EXAMPLE 5
  • The procedure of Example 1 is repeated except that the following components are used: [0339]
    VIP-Gly-Cys-NO (SEQ. ID NO.: 203) 750 mg
    Polyethylene glycol 400 47.5 g
    Cetyl Alcohol 5.0 g
    Polyethylene glycol 4000 q.s. 100.0 g
  • VIP-Gly-Cys-NO (SEQ. ID NO.: 203) is prepared as described in U.S. Pat. No. 5,612,314 to Stamler et al. A homogenous cream mixture is obtained. [0340]
    • EXAMPLE 6
  • An ointment formulation is prepared for the topical administration of VIP. The ointment includes the following components: [0341]
    VIP 750 mg
    Anhydrous lanolin 20.0 g
    Mineral oil 25.0 g
    White Petrolatum q.s. 100.0 g
  • Mixing is conducted with tile and spatula until a homogeneous ointment mixture is obtained having the VIP uniformly dispersed throughout the composition. [0342]
    • EXAMPLE 7
  • The procedure of Example 5 is repeated except that the following components are used: [0343]
    VIP 750 m
    Diisopropyl Adipate 19.95 g
    White Petrolatum, USP q.s. 100.0 g
  • A homogenous ointment mixture is obtained. [0344]
  • In the cream and ointment formulations described in Examples 1-6, optional ingredients can include materials such as antioxidants, viscosity modifiers (e.g., paraffin wax or lanolin wax), and topical absorption rate modifiers. [0345]
    • EXAMPLE 8
  • A vaginal suppository formulation is prepared using a synthetic or semisynthetic prostaglandin. The suppository includes the following components: [0346]
    Prostaglandin 0.25 gm
    Polyethylene glycol 400 37.0 gm
    Glycerol gelatin 20.0 gm
    Polyethylene glycol 4000 q.s. 100.0 gm
  • The polyethylene glycol 400 solution containing prostaglandin is mixed well with glycerol gelatin or similar suppository base such as macrogol, Witepsol®, or the like, with a mechanical mixing apparatus, and the mixture is then cooled in a suppository mold. [0347]
    • EXAMPLE 9
  • Suppositories suitable for vaginal administration of a unit dosage of VIP are made as follows. Twenty mg VIP are mixing the selected prostaglandin with 250 mg polyethylene glycol, molecular weight (M[0348] w) approximately 4000, and the mixture is heated to a temperature just high enough to produce a melt. The melted mixture is then poured into a mold suitable to provide a suppository, and allowed to cool. The suppository so provided is a unit dosage form suitable for vaginal administration.
    • EXAMPLE 10
  • Individuals are assessed and pre-screened to assemble an experimental group of subjects suffering from sexual dysfunction. The compositions prepared in Examples 1-9, formulated with VIP or an analog thereof, are each assessed in the experimental subjects for their ability to increase uterine or vaginal epithelial blood flow. The formulations are applied vaginally and to the vulvar region, and changes in blood flow and/or vaginal fluid production after application of the vasodilating formulations are determined using known methods. Increase in vaginal epithelial blood flow is determined using indirect methods such as photoplethysmography (Levin (1980) [0349] Clinics in Obstet. Gynaecol. 7:213-252), heated oxygen electrode (Wagner et al. (1978), “Vaginal Fluid” in The Human Vagina, Evans et al. (eds.), Amsterdam: Elsevier/North Holland Biomedical Press, pp. 121-137), and direct clearance of radioactive Xenon (Wagner et al. (1980) Obstet. Gynaecol. 56:621-624). Changes in vulvar blood flow are monitored using laser Doppler velocimetry (Sarrel, P. M. (1990) Obstet. Gynaecol. 75:26S-32S).
  • Decreased vaginal dryness and/or dyspareunia are negatively correlated with vaginal blood flow rates, wherein increased blood flow to the vagina correlates with increased lubrication and decreased frequency and severity of dyspareunia (Sarrel, P. M. (1990) [0350] Obstet. Gynaecol. 75:26S-32S). Accordingly, vulvar blood flow after treatment is assessed using laser Doppler velocimetry and compared to baseline levels. Increased vaginal lubrication as a result of treatment with the vasoactive formulations can also be assessed using the methods of Semmens et al. (1982) J. Am. Med. Assoc. 248:445-448. The compositions of Examples 1-9, when assessed using such methods, are found to substantially increase blood flow to the vagina and vulvar area and alleviate vaginal dryness.

Claims (40)

1. A method for treating sexual dysfunction in a female individual, comprising administering to the vagina and/or vulvar region of the individual a pharmaceutical formulation that comprises a therapeutically effective amount of a vasoactive agent selected from the group consisting vasoactive intestinal polypeptide and agonists thereof.
2. The method of claim 1, wherein the pharmaceutical formulation further includes a pharmaceutically acceptable carrier suited to vaginal and/or vulvar drug administration.
3. The method of claim 1, flurther including administering a steroid to the vagina and/or vulvar region of the individual.
4. The method of claim 3, wherein the steroid is selected from the group consisting of progestins, estrogens, androgens, and combinations thereof.
5. The method of claim 1, wherein the pharmaceutical formulation further includes a compound selected from the group consisting of steroid agonists, partial agonists and antagonists.
6. The method of claim 1, wherein the pharmaceutical formulation is contained within a delivery system selected to provide a predetermined agent release profile.
7. The method of claim 6, wherein the agent release profile is pulsatile.
8. The method of claim 6, wherein the agent release profile is continuous.
9. The method of claim 6, wherein the agent release profile is cyclical.
10. The method of claim 6, wherein the agent release profile is diurnal.
11. The method of claim 1, wherein the pharmaceutical formulation is administered vaginally.
12. The method of claim 11, wherein the pharmaceutical formulation is in the form of an ointment, cream, gel, solid, solution, suspension, foam or liposomal composition.
13. The method of claim 11, wherein the pharmaceutical formulation is contained within a vaginal ring, tampon, suppository, sponge, pillow, puff, or osmotic pump system.
14. The method of claim 1, wherein the pharmaceutical formulation is administered to the vulvar region.
15. The method of claim 1, wherein the vasoactive agent is vasoactive intestinal polypeptide.
16. The method of claim 1, wherein the vasoactive agent is a vasoactive intestinal polypeptide agonist.
17. The method of claim 16, wherein the vasoactive intestinal polypeptide agonist comprises a polypeptide sequence comprising a human vasoactive intestinal polypeptide sequence having amino acid substitutions at one or more positions.
18. The method of claim 17, wherein the vasoactive intestinal polypeptide agonist is terminally modified.
19. The method of claim 16, wherein the vasoactive intestinal peptide agonist comprises at least one agonist selected from the group consisting of SEQ. ID. NOS.:2-205 inclusive.
20. The method of claim 4, wherein the steroid is an androgenic agent.
21. The method of claim 20, wherein the androgenic agent is selected from the group consisting of androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3-acetate, androstenediol-17-acetate, androstenediol-3,17-diacetate, androstenediol-17-benzoate, androstenediol-3-acetate-17-benzoate, androstenedione, dehydroepiandrosterone, sodium dehydroepiandrosterone sulfate, 4-dihydrotestosterone, dromostanolone, dromostanolone propionate, ethylestrenol, fluoxymesterone, methyltestosterone, nandrolone phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexane-propionate, nandrolone benzoate, nandrolone cyclohexanecarboxylate, oxandrolone, oxymetholone, stanozolol, testolactone, testosterone, and pharmaceutically acceptable esters of testosterone and 4-dihydrotestosterone.
22. The method of claim 21, wherein the androgenic agent is selected from the group consisting of testosterone, C-17 esters of testosterone, 4-dihydrotestosterone, C-17 esters of 4-dihydrotestosterone, dehydroepiandrosterone, and methyltestosterone.
23. A method for enhancing sexual desire and responsiveness in a female individual, comprising administering to the individual, approximately 0.25 to 72 hours prior to sexual activity, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
24. A method for maintaining improving the tissue health of the female genitalia, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
25. A method for preventing vaginal atrophy, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
26. A method for preventing vaginal pain during sexual intercourse, comprising administering to a female individual suffering from dyspareunia a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
27. A method for alleviating vaginal itching and dryness, comprising administering to a female individual in need of such treatment a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof, on an as-needed basis.
28. A method for enhancing sexual desire and responsiveness in a female individual, comprising administering a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof to the individual in an amount effective to provide a blood level of the agent or a metabolite thereof that approximates the blood level of the agent or a metabolite thereof during ovulation.
29. A pharmaceutical formulation for enhancing female sexual desire and responsiveness, comprising (a) approximately 1.0 μg to 1.0 g of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof, per gram of formulation, (b) a pharmaceutically acceptable carrier suitable for vaginal and/or vulvar administration.
30. The formulation of claim 29, wherein the formulation comprises approximately 50 μg to about 500 mg of the vasoactive agent per gram of formulation.
31. The formulation of claim 30, wherein the formulation comprises approximately 1.0 mg to about 250 mg of the vasoactive agent per gram of formulation.
32. The formulation of claim 29, wherein the carrier is selected to provide immediate release of the vasoactive agent from the formulation following application to the individual's vagina and/or vulvar area, such that the formulation may be effectively administered on an on-demand basis.
33. The formulation of claim 29, comprising a gel, cream, ointment, solution or lotion.
34. The formulation of claim 29, comprising a suppository.
35. The formulation of claim 29, wherein the vasoactive agent is vasoactive intestinal polypeptide.
36. The formulation of claim 29, wherein the vasoactive agent is a vasoactive intestinal polypeptide agonist.
37. The formulation of claim 36, wherein the vasoactive intestinal polypeptide agonist comprises a polypeptide sequence comprising a human vasoactive intestinal polypeptide sequence having amino acid substitutions at one or more positions.
38. The formulation of claim 37, wherein the vasoactive intestinal polypeptide agonist is terminally modified.
39. The formulation of claim 36, wherein the vasoactive intestinal peptide agonist comprises at least one agonist selected from the group consisting of SEQ. ID. NOS.:2-205 inclusive.
40. A packaged kit for a female individual to use in enhancing sexual desire and responsiveness, comprising: a pharmaceutical formulation of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide and agonists thereof; a container housing the pharmaceutical formulation during storage and prior to administration; and instructions for carrying out drug administration to enhance sexual desire and responsiveness.
US09/929,818 1997-10-28 2001-08-13 Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof Abandoned US20020099003A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/929,818 US20020099003A1 (en) 1997-10-28 2001-08-13 Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US11/262,067 US7226910B2 (en) 1997-10-28 2005-10-28 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95905797A 1997-10-28 1997-10-28
US08/959,064 US5877216A (en) 1997-10-28 1997-10-28 Treatment of female sexual dysfunction
US18131698A 1998-10-27 1998-10-27
US49852200A 2000-02-04 2000-02-04
US09/929,818 US20020099003A1 (en) 1997-10-28 2001-08-13 Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US49852200A Continuation-In-Part 1997-10-28 2000-02-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/262,067 Continuation US7226910B2 (en) 1997-10-28 2005-10-28 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists

Publications (1)

Publication Number Publication Date
US20020099003A1 true US20020099003A1 (en) 2002-07-25

Family

ID=27497445

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/929,818 Abandoned US20020099003A1 (en) 1997-10-28 2001-08-13 Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US11/262,067 Expired - Fee Related US7226910B2 (en) 1997-10-28 2005-10-28 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/262,067 Expired - Fee Related US7226910B2 (en) 1997-10-28 2005-10-28 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists

Country Status (1)

Country Link
US (2) US20020099003A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2006091795A2 (en) * 2005-02-25 2006-08-31 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS
US20070254953A1 (en) * 2003-08-13 2007-11-01 Perrigo Israel Pharmaceuticals Ltd. Topical compositions of urea and ammonium lactate
US20070270394A1 (en) * 2004-10-20 2007-11-22 Endorecherche, Inc. Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20090054383A1 (en) * 2007-08-10 2009-02-26 Endorecherche, Inc. Pharmaceutical compositions
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
WO2011020091A1 (en) * 2009-08-14 2011-02-17 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US8361273B2 (en) 2006-07-08 2013-01-29 Ferring B.V. Polyurethane elastomers
US8460707B2 (en) 2004-08-05 2013-06-11 Ferring B.V. Stabilised prostaglandin composition
WO2013098592A1 (en) * 2011-12-29 2013-07-04 Universidad De Chile Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US8524254B2 (en) 2006-10-18 2013-09-03 Ferring B.V. Bioresorbable polymers
US8557281B2 (en) 2002-09-27 2013-10-15 Ferring B.V. Water-swellable polymers
US8974813B2 (en) 2006-07-05 2015-03-10 Ferring B.V. Hydrophilic polyurethane compositions
US9821036B2 (en) 2008-06-27 2017-11-21 Duke University Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides
US20190099432A1 (en) * 2016-05-02 2019-04-04 T & A Pharma Pty Limited Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
US10258700B2 (en) 2005-12-20 2019-04-16 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2019226548A1 (en) * 2018-05-22 2019-11-28 Weinberg Assa Methods for prevention and treatment of urogenital atrophy of menopause by contact vasodilators
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
US10940182B2 (en) 2011-06-06 2021-03-09 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US11426394B2 (en) 2018-12-09 2022-08-30 Assa Weinberg Method to prevent and treat macular degeneration by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
ES2779992T3 (en) 2005-12-20 2020-08-21 Univ Duke Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
AU2009257631B2 (en) * 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (en) * 2008-06-09 2010-08-04 Palatin Technologies Inc SPECIFIC PEPTIDES OF THE MELANOCORTINE RECEPTOR FOR THE TREATMENT OF OBESITY / 669
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
US20110002966A1 (en) * 2009-07-01 2011-01-06 Alex Lovett Vaginal Suppository System and Method
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102712674A (en) 2009-11-23 2012-10-03 帕拉丁科技公司 Melanocortin-1 receptor-specific linear peptides
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217953A (en) * 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5376637A (en) * 1991-04-22 1994-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical preparation containing vasoactive intestinal polypeptide or its analogue
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
US5565424A (en) * 1994-02-07 1996-10-15 Ramot - University Authority For Applied Research And Industrial Development Ltd. Superactive VIP antagonists
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6051555A (en) * 1993-04-05 2000-04-18 Hadley; Mac E. Stimulating sexual response in females
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6239107B1 (en) * 1996-04-23 2001-05-29 Yeda Research & Development Co., Ltd. Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
US6266560B1 (en) * 1998-06-19 2001-07-24 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US6300335B1 (en) * 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295317A1 (en) 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmaceutical composition for the treatment of tumors
EP0755685A4 (en) 1994-04-15 2000-05-03 Meiji Seika Kaisha Medicinal composition for treating tardive dyskinesia and utilization thereof
US5612314A (en) * 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
WO2001017479A2 (en) 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
WO2001090144A2 (en) 2000-05-22 2001-11-29 Ramot At Tel-Aviv University Ltd. Vip-related peptides for the treatment of sexual disorders in women

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
US5217953A (en) * 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5376637A (en) * 1991-04-22 1994-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical preparation containing vasoactive intestinal polypeptide or its analogue
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US6051555A (en) * 1993-04-05 2000-04-18 Hadley; Mac E. Stimulating sexual response in females
US5565424A (en) * 1994-02-07 1996-10-15 Ramot - University Authority For Applied Research And Industrial Development Ltd. Superactive VIP antagonists
US6300335B1 (en) * 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
US6239107B1 (en) * 1996-04-23 2001-05-29 Yeda Research & Development Co., Ltd. Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6266560B1 (en) * 1998-06-19 2001-07-24 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987364B2 (en) 2002-09-27 2018-06-05 Ferring B.V. Water-swellable polymers
US8628798B2 (en) 2002-09-27 2014-01-14 Ferring B.V. Water-swellable polymers
US8557281B2 (en) 2002-09-27 2013-10-15 Ferring B.V. Water-swellable polymers
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20070254953A1 (en) * 2003-08-13 2007-11-01 Perrigo Israel Pharmaceuticals Ltd. Topical compositions of urea and ammonium lactate
US8709482B2 (en) 2004-08-05 2014-04-29 Ferring B.V. Stabilised prostaglandin composition
US8491934B2 (en) 2004-08-05 2013-07-23 Ferring B.V. Stabilised prostaglandin composition
US8460707B2 (en) 2004-08-05 2013-06-11 Ferring B.V. Stabilised prostaglandin composition
US20070270394A1 (en) * 2004-10-20 2007-11-22 Endorecherche, Inc. Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US10478443B2 (en) 2004-10-20 2019-11-19 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women
US10076525B2 (en) 2004-10-20 2018-09-18 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20080269121A1 (en) * 2005-02-25 2008-10-30 The Board Of Regents Of The University Of Texas System Methods and Compositions Involving A1c Subunit of L-Type Calcium Channels in Smooth Muscle Cells
WO2006091795A3 (en) * 2005-02-25 2007-07-12 Univ Texas METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS
WO2006091795A2 (en) * 2005-02-25 2006-08-31 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS
US10258700B2 (en) 2005-12-20 2019-04-16 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US10105445B2 (en) 2006-07-05 2018-10-23 Ferring B.V. Hydrophilic polyurethane compositions
US8974813B2 (en) 2006-07-05 2015-03-10 Ferring B.V. Hydrophilic polyurethane compositions
US8361272B2 (en) 2006-07-08 2013-01-29 Ferring B.V. Polyurethane elastomers
US8361273B2 (en) 2006-07-08 2013-01-29 Ferring B.V. Polyurethane elastomers
US8524254B2 (en) 2006-10-18 2013-09-03 Ferring B.V. Bioresorbable polymers
US20090054383A1 (en) * 2007-08-10 2009-02-26 Endorecherche, Inc. Pharmaceutical compositions
US8629129B2 (en) 2007-08-10 2014-01-14 Endorecherche, Inc. Pharmaceutical compositions
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US10881650B2 (en) 2007-08-10 2021-01-05 Endorecherche, Inc. Pharmaceutical compositions
US8957054B2 (en) 2007-08-10 2015-02-17 Endorecherche, Inc. Pharmaceutical compositions
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US9821036B2 (en) 2008-06-27 2017-11-21 Duke University Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides
US11103558B2 (en) 2008-06-27 2021-08-31 Duke University Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
US10596230B2 (en) 2008-06-27 2020-03-24 Duke University Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides
US20110178017A1 (en) * 2009-08-14 2011-07-21 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
AU2017279636B2 (en) * 2009-08-14 2019-09-12 Immunoforge Co., Ltd. Modified Vasoactive Intestinal Peptides
WO2011020091A1 (en) * 2009-08-14 2011-02-17 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
AU2016200897B2 (en) * 2009-08-14 2017-10-12 Immunoforge Co., Ltd. Modified Vasoactive Intestinal Peptides
RU2589255C2 (en) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Modified vasoactive intestinal peptides
AU2010282250B2 (en) * 2009-08-14 2015-11-12 Immunoforge Co., Ltd. Modified Vasoactive Intestinal Peptides
US9700598B2 (en) 2009-08-14 2017-07-11 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US9029505B2 (en) 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CN102596217A (en) * 2009-08-14 2012-07-18 费斯生物制药公司 Modified vasoactive intestinal peptides
CN102596217B (en) * 2009-08-14 2014-07-02 费斯生物制药公司 Modified vasoactive intestinal peptides
US10940182B2 (en) 2011-06-06 2021-03-09 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CN104271084A (en) * 2011-12-29 2015-01-07 智利大学 Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
WO2013098592A1 (en) * 2011-12-29 2013-07-04 Universidad De Chile Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US9066956B2 (en) 2011-12-29 2015-06-30 Universidad De Chile Vaginal ring comprising DHEA or DHEA sulfate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
EA027633B1 (en) * 2011-12-29 2017-08-31 Универсидад Де Чиле Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
US11266719B2 (en) 2015-02-09 2022-03-08 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
US20190099432A1 (en) * 2016-05-02 2019-04-04 T & A Pharma Pty Limited Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
US11273164B2 (en) * 2016-05-02 2022-03-15 TA Pharma Pty Limited Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
WO2019226548A1 (en) * 2018-05-22 2019-11-28 Weinberg Assa Methods for prevention and treatment of urogenital atrophy of menopause by contact vasodilators
US11426394B2 (en) 2018-12-09 2022-08-30 Assa Weinberg Method to prevent and treat macular degeneration by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers

Also Published As

Publication number Publication date
US7226910B2 (en) 2007-06-05
US20060041021A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
US7226910B2 (en) Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
US20020013304A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20030022875A1 (en) As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
US20050070516A1 (en) As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5877216A (en) Treatment of female sexual dysfunction
US6294550B1 (en) Treatment of female sexual dysfunction
US20040044080A1 (en) Treatment of dyspareunia with topically administered nitroglycerin formulations
JP5441966B2 (en) Uses and formulations for transdermal or transmucosal application of active agents
US6284263B1 (en) Buccal drug administration in the treatment of female sexual dysfunction
US20070036848A1 (en) Estrogen compositions and therapeutic methods of use thereof
US20040014761A1 (en) Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20080085877A1 (en) Therapeutic methods of using estrogen compositions
US20080287408A1 (en) Endometriosis treatment
AU2002313708A1 (en) As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
AU2002313709A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
WO2008018872A1 (en) Therapeutic methods of using estrogen compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: VIVUS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILSON, LELAND F.;PLACE, VIRGIL A.;REEL/FRAME:012180/0964

Effective date: 20011116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION